

AD\_\_\_\_\_

Award Number: DAMD17-99-1-9201

TITLE: Altered Cdc42 Signaling in Metastatic Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Dana M. Pirone

CONTRACTING ORGANIZATION: Georgetown University Medical Center  
Washington, DC 20057

REPORT DATE: July 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020816 094

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> July 2001	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (1 Jul 99 - 30 Jun 01)	
<b>4. TITLE AND SUBTITLE</b> Altered Cdc42 Signaling in Metastatic Breast Cancer Cells			<b>5. FUNDING NUMBERS</b> DAMD17-99-1-9201	
<b>6. AUTHOR(S)</b> Dana M. Pirone				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Georgetown University Medical Center Washington, DC 20057  E-Mail: pironed@georgetown.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> The ability of cells to change their shape and move is critical to many biological processes. Cancer metastasis, the process whereby cancer cells leave a primary tumor and proliferate at distant sites, is highly dependent on cell shape changes and cell motility. The Rho GTPases play major roles in regulating the organization of the actin cytoskeleton and cell motility. Cdc42, one of the Rho GTPases, exerts its biological effects through interaction with downstream effector proteins. We identified a new family of Cdc42 effector proteins called SPECs for Small Protein Effector of Cdc42. The two human members of this family, SPEC1 and SPEC1 contain a centrally located CRIB domain through which they bind Cdc42. Overexpression of SPEC1 and SPEC2 in NIH-3T3 fibroblasts resulted in the formation of plasma membrane blebbing and modified Cdc42-induced biological activities when co-expressed with Cdc42. JNK kinase assays revealed that SPEC1 inhibited Cdc42-induced JNK activation. Northern blot analysis showed that SPEC1 is alternatively spliced and exists in at least four different molecular weight species. Additional Northern blot data using RNA from a panel of breast cancer cell lines suggests that SPEC1 expression may decrease in more metastatically aggressive breast cancer cell lines.				
<b>14. SUBJECT TERMS</b> Cdc42, metastasis, actin, cytoskeleton				<b>15. NUMBER OF PAGES</b> 33
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

**Table of Contents**

Coversheet	1
SF 298	2
Table of Contents	3
Introduction	4
Body	5
Key Research Accomplishments	12
Reportable Outcomes	13
Conclusions	14
References	15
Appendices	18

### Introduction

As research in the field of cancer treatment progresses, new therapeutics are continually being developed to fight cancer. Despite these advances, cancer metastasis remains a major obstacle to effective cancer treatment and the major cause of cancer mortality. Cancer metastasis is the process whereby cancer cells leave a primary tumor, enter the circulation, extravasate and proliferate at distant sites (Fidler et al., 1978). At a cellular level, the acquisition of a motile and invasive phenotype requires the abrogation of cell-cell contacts, the remodeling of the extracellular matrix, and changes in cell-matrix interactions, leading ultimately to the reorganization of the actin cytoskeleton and cell motility. A family of proteins called the Rho GTPases play major roles in regulating these very processes, including the regulation of the actin cytoskeleton leading to cell shape changes, the establishment of cell-cell contacts, cell-matrix interactions, and cell polarization (reviewed in Van Aelst et al., 1997). Because of the participation of the Rho GTPases in cellular processes involved in cell motility and migration, it is not unlikely that the aberrant regulation of the Rho GTPase signaling pathways may play critical roles in cancer metastasis. Thus, understanding the proteins that bind and regulate the Rho GTPases is critical to our understanding of cell motility as well as having exciting potential applications for cancer metastasis.

The Rho GTPases belong to the Ras superfamily of small G proteins that function as molecular switches to relay signals downstream of transmembrane receptors. The prototypical members of this family, Rho, Rac, and Cdc42 play a role in cell motility by regulating structures formed by the cortical actin cytoskeleton. In Swiss 3T3 fibroblasts, microinjection of Cdc42 leads to the formation of filopodia, microinjection of Rac induces the formation of lamellipodia, and microinjection of Rho causes the formation of stress fibers (Kozma et al., 1995; Nobes and Hall, 1995). Furthermore, in Swiss 3T3 fibroblasts, these GTPases cross-activate each other in a cascade fashion, where activation of Cdc42 leads to activation of Rac and subsequent activation of Rho (Nobes and Hall, 1995). Thus, Rho GTPases work cooperatively to mediate the process of cell motility (Nobes and Hall 1999). In addition to their effects on the actin cytoskeleton, the Rho GTPases are also implicated in a variety of other signaling pathways, including the assembly of focal adhesions complexes (Nobes and Hall, 1995) the assembly of cadherin-containing cell-cell contacts (Takaishi et al., 1997; Braga et al., 1997), cell polarity (Nobes and Hall, 1999; Qiu et al., 2000), and kinase signaling pathways including c-jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (Coso et al., 1995; Minden et al., 1995).

The mechanism through which Cdc42 exerts its effects on both cytoskeletal rearrangement and kinase signaling pathways is through its interaction with downstream effector proteins. A general feature of Cdc42 effector proteins is the presence of a conserved 16 amino acid Cdc42 binding domain termed a CRIB (Cdc42/Rac Interactive Binding) domain (Burbelo et al., 1995). Cdc42 mediates a diverse array of biological activities because of its interaction with a large repertoire of over 25 effector proteins identified to date. Binding of activated Cdc42 to the CRIB domain of kinase effectors including PAK (Manser et al., 1997; Martin et al., 1995) activates the kinase activity of these proteins (Bagrodia et al., 1995; Brown et al., 1996; Lei et al., 2000). Other non-kinase effectors of Cdc42 such as WASP (Symons et al., 1996) and N-WASP (Miki et al., 1996) link Cdc42 to actin nucleation via the WASP/Arp2/3 complex interaction (Rohatgi et al., 1999; Higgs and Pollard 1999; Prehoda et al., 2000). Taken together, these studies demonstrate that CRIB-containing effector proteins regulate multiple biological activities including cytoskeletal organization and kinase signaling.

To identify new signaling molecules that function directly downstream of Cdc42, we searched the NCBI EST database using the CRIB domain of the non-kinase Cdc42 effector proteins MSE55/CEP1 (Burbelo et al., 1999) for cDNAs that shared homology within this region. Using this approach, we identified two genes that comprise a new family of Cdc42 effector proteins. These proteins are designated SPECs for Small Protein Effector of Cdc42. There are two human members of this family, SPEC1 and SPEC2 that are 79 and 84 amino acids respectively. Both SPEC proteins contain a centrally located CRIB domain through which they bind Cdc42. Northern blot data and DNA sequence analysis revealed that there are several splice variants of SPEC1. One of these variants, designated SPEC1- $\beta$  potentially encodes a 38 amino acid protein, lacking a CRIB



domain, but containing the same first 18 amino acids as SPEC1. Early studies on this work indicated that the ratio of SPEC1 to SPEC1- $\beta$  isoforms may be altered in more metastatically aggressive breast cancer cell lines, where SPEC1- $\beta$  is more highly expressed in the highly metastatic MDA-231 and MDA-435 breast cancer cell lines as compared to the less aggressive T47D and MCF-7 breast cancer cell lines. As proposed in our original statement of work, there are three specific aims for this research: 1. We will test the hypothesis that SPEC1 and SPEC1- $\beta$  proteins affect actin organization, cell shape, and cell movement in breast cancer cells. 2. We will examine the effect of SPEC1 and SPEC1- $\beta$  on kinase signaling pathways and transcriptional activation. 3. We will test the hypothesis that the levels of SPEC1 and SPEC1- $\beta$  proteins in different breast cancer cell lines correlate with breast cancer aggressiveness.

## Body

**Specific Aim 1:** We will test the hypothesis that SPEC1 and SPEC1- $\beta$  proteins affect actin organization, cell shape, and cell movement in breast cancer cells.

### Results for Specific Aim1:

We examined the cellular distribution of epitope-tagged SPEC1 expression by immunofluorescence in Cos1 cells. In Cos1 cells, SPEC1 showed diffuse cytoplasmic localization (Figure 1). SPEC-expressing cells did not show altered actin structures or cell morphology in Cos1 cells or in MCF-7 breast cancer cells (data not shown). We next determined whether SPEC1 influenced Cdc42 function when co-expressed with Cdc42. Cos1 cells expressing the constitutively active Cdc42-Q61L mutant exhibited a widely spread and flattened phenotype with some filopodia (Figure 1). Cotransfection of SPEC1 with Cdc42-Q61L resulted in cells that were much less spread than cells expressing Cdc42-Q61L alone (compare Figure 1, C and D with Figure 1A) or untransfected cells (data not shown). In contrast to what was seen with wild type SPEC1, cells coexpressing Cdc42-Q61L and the CRIB domain mutant (SPEC1-H38A) resembled cells transfected with Cdc42-Q61L alone (compare Figure 1, E and F with Figure 1A). These results suggest that SPEC1 modifies Cdc42 function. In these experiments SPEC1 appears to alter Cdc42 activity by binding to it via the CRIB domain. These results suggest that SPECs may function to block the interaction of Cdc42 with other effector proteins, although we can not rule out the possibility that the observed blocking activity was due to overexpression of SPEC1 protein.




Figure 1: SPEC1 alters Cdc42 activity in Cos1 cells

Since SPEC1 expression did not noticeably alter the morphology of Cos1 cells or MCF-7 breast cancer cells, we studied the effects of SPEC1 expression in NIH-3T3 fibroblasts. In NIH-3T3 fibroblasts, SPEC1 displayed a predominant cortical localization (Figure 2) and frequently, these transfected cells showed extensive membrane blebbing (Figure 2). F-actin stained strongly within the periphery of the blebs, but not within the blebs (Figure 2). Expression of SPEC2 also showed the same cortical localization, membrane blebbing and F-actin staining phenotype (Figure 2, C and D). A similar pattern of cortical staining and blebbing were observed with a myc epitope tag located either at the N- or C-terminus of SPEC1 and using a 20-fold range of plasmid concentrations (100 ng to 2  $\mu$ g; data not shown). Although this SPEC-induced membrane blebbing is morphologically similar to the membrane blebbing associated with apoptosis, there is no functional association of the SPEC-induced




Figure 2: SPEC1 and SPEC2 induce membrane blebbing in NIH-3T3 ifibroblasts

blebbing with apoptosis. That is, neither nuclear condensation following DAPI staining of nuclei nor annexin-V positive staining, a marker for phosphatidylserine flipping in the membrane, was observed in these transfected cells (data not shown).

Quantitatively, membrane blebbing was observed in 40-60% of the Flag epitope-tagged SPEC1 transfected cells but only in about 5% of cells expressing the vector-alone control (Figure 3). We also used a bicistronic expression vector, expressing both SPEC1 and Enhanced Green Fluorescent Protein (EGFP) from the same vector, to rule out the possibility that the epitope tags might influence SPEC function. About 40% of the cells expressing the bicistronic SPEC1 construct showed a blebbing phenotype, while only 10% were blebbing with the EGFP-alone vector (Figure 3). Taken together, these results demonstrate that expression of SPECs, whether epitope-tagged or untagged leads to membrane blebbing in NIH-3T3 fibroblasts.

In order to determine whether any of the three conserved regions in SPECs are necessary for SPEC1-induced membrane blebbing, we examined the phenotype of cells transfected with various SPEC1 mutants. An additional, N-terminal mutant, SPEC1-C10A, C11A was created within two conserved cysteine residues because of the potential role of these residues in lipid modification or protein interactions. Using cell counting it was found that both the positive and negative controls gave the expected results: approximately 44% of N-terminal Flag-tagged SPEC1-transfected cells blebbed, as compared to only 4% using a vector-alone control (Figure 4). The C-terminal double point mutant, SPEC1-Q62A, K66A, had no effect on the level of blebbing (Figure 4). In contrast, the cells expressing the N-terminal mutant (SPEC1-C10A, C11A), which showed a similar level of expression and cortical localization, produced the blebbing




Figure 3: Quantitative analysis of the effect of tagged and untagged SPEC1 on blebbing




Figure 4: Activity of different SPEC1 mutants on inducing membrane blebbing

phenotype in only 20% of the transfected cells (Figure 4). Single or triple amino acid substitutions within the CRIB domain of SPEC1 resulted in somewhat fewer blebs, although they still produced significantly more than the negative controls (30% vs. 4%; Figure 4). Additional studies expressing a dominant negative mutant of Cdc42 (Cdc42-T17N) alone did not induce membrane blebbing and co-expression with SPEC1 did not block membrane blebbing (data not shown). These results support a model whereby SPEC1-induced blebbing does not occur through classical Cdc42-effector interactions and suggest that SPEC1 may act independently of Cdc42 or perhaps upstream of Cdc42 to induce membrane blebbing. These data also confirm that SPEC-induced membrane changes are not directly due to sequestration of Cdc42.

To define the relationship between Cdc42 activity and SPECs, we tested the effect of SPEC1/Cdc42 co-expression in NIH-3T3 fibroblasts. In fibroblasts, expression of Cdc42L61 resulted in cells that predominantly exhibited a membrane ruffling phenotype, possibly through activation of Rac signaling. We cotransfected SPEC1 or the SPEC1-CRIB mutants (SPEC1-H38A or SPEC1-P33A, H38A, H41A) with constitutively active Cdc42 and quantified the number of transfected cells showing a ruffling phenotype. Expression of a constitutively active Cdc42 mutant (Cdc42-Q61L), but not wild type Cdc42 (data not shown), in NIH-3T3 fibroblasts induced membrane ruffling in 52% of the transfected cells (Figure 5, A and B). Co-transfection of SPEC1 blocked




Figure 5: SPEC1 alters Cdc42-induced cell shape changes

ruffling in all but 5% of the transfected cells and increased the number of blebbing cells (Figure 5, C and D). Coexpression of the SPEC-H38A mutant resulted in 34% of the cells showing a membrane ruffling phenotype (Figure 5, E and F) and resembled cells transfected with Cdc42 alone (compare Figure 5, A and B with Figure 5, E and F). Similar results were obtained with the SPEC1-P33A,H38A,H41A CRIB mutant (data not shown). In these cotransfections experiments, SPEC1 and Cdc42 proteins appear to localize to similar regions within the cells, suggesting that SPECs and Cdc42 may be contained within the same signaling complexes (Figure 5). As with Cos1 cells, these transfections demonstrate that SPEC1 expression led to an altered Cdc42-induced morphology and that this alteration is dependent on the presence of an intact CRIB domain.


Although we were able to obtain high levels of SPEC1 expression in several different mammalian cell types, we were not able to observe consistently high expression of SPEC1- $\beta$ . In the attempted SPEC1- $\beta$  transfections, only very few cells were expressing the SPEC1- $\beta$  protein, however, in these cells the overall morphology of the cells and actin cytoskeletal organization was apparently normal (data not shown). Despite this particular setback, these studies overall show that SPEC1 overexpression alters or reverses the cellular morphologies produced when Cdc42 is overexpressed in Cos1 cells and in NIH-3T3 fibroblasts. The membrane blebbing induced by SPEC1 overexpression in NIH-3T3 fibroblasts was not observed in Cos1 cells, possibly due to quantitative differences in expression levels of SPEC proteins between the two cell types. Nevertheless, these results show that SPECs are capable of modifying Cdc42-dependent signaling at both the biochemical and cellular levels in a CRIB-dependent manner. SPEC binding may prevent the interaction of Cdc42 with other effector proteins. Consistent with this model, a polypeptide containing just the CRIB domain of PAK can effectively inhibit Cdc42 activation of JNK kinase (Minden et al., 1995) and block transcriptional activation (Osada et al., 1997), while a polypeptide containing the CRIB domain of ACK-1 can act as a Cdc42-specific inhibitor, blocking v-Ha-Ras-induced transformation (Nur-E-Kamal et al., 1999).

However, we do not know if the specific biochemical and biological effects observed here, with overexpressed SPECs, reflect the normal function of these small proteins. In particular, SPEC overexpression induced membrane blebbing in NIH-3T3 fibroblast, which was not blocked by dominant negative Cdc42 expression. Despite these findings, it is still possible that SPECs function in Cdc42-induced morphological changes, since a dominant negative approach may not rescue the abnormal morphology of overexpressed SPEC protein. Furthermore, various studies have shown that non-apoptotic membrane blebs function normally in cell spreading (Erickson et al., 1976; Cunningham, 1995) and locomotion (Trinkaus, 1980; Keller and Eggl, 1998; Cunningham et al., 1992). Mechanistically membrane blebs occur at sites where the cortical actin is locally depolymerized or detached from the membrane (Cunningham, 1995; Keller and Eggl, 1998; Cunningham et al., 1995) via alteration in cortical actin binding proteins (Keller and Eggl, 1998), myosin light chain kinase activity (Mills et al., 1998; Huot et al., 1998) and/or focal complex assembly (Huot et al., 1998). Thus, it is possible that SPEC1 and SPEC2 may function as classical Cdc42 effector proteins by altering the normal signaling pathways leading to actin, myosin and/or focal complex assembly.

Specific Aim 2: We will examine the effect of SPEC1 and SPEC1- $\beta$  on kinase signaling pathways and transcriptional activation.

#### Results for Specific Aim 2:

Since a variety of studies have shown both that Cdc42 (Coso et al., 1995; Minden et al., 1995) and some Cdc42 effector proteins (Teramoto et al., 1996; Bagrodia et al., 1995; Zhang et al., 1995; Brown et al., 1996) can activate JNK activity, we tested SPEC1 and several SPEC1 mutants for their effect on Cdc42-induced JNK activation. First, an expression construct of human SPEC1 carrying an N-terminal FLAG-epitope tag was transfected



into NIH-3T3 fibroblasts and its expression analyzed by Western blotting using a monoclonal antibody against the N-terminal FLAG epitope tag. Using this approach, SPEC1 was detected in lysates as an ~8 kD species (data not shown), of which about 1 kb is contributed by the epitope tag. Second, several SPEC1 mutants were constructed including two CRIB mutants and a C-terminal double mutant. The two CRIB mutants, SPEC1-H38A and SPEC1-P33A,H38A,H41A, contain alanine substitutions within critical contact sites known to be involved in Cdc42 binding (Abdul-Manan et al., 1999; Mott et al., 1999). The third mutant, SPEC1-Q62A,K66A, contained mutations within the 9 amino acid region conserved between both SPEC proteins that might be part of an extended high affinity Cdc42 binding site. Cos1 cells were cotransfected with the expression vectors for GFP (control) or Cdc42-Q61L, hemagglutinin (HA) epitope-tagged JNK and Flag-tagged SPEC1 constructs. After 24 hours, transiently expressed HA-JNK was isolated by immunoprecipitation and used for *in vitro* kinase assays. All SPEC1 constructs tested were not able stimulate JNK activity on their own (Figure 6A). Expression of Cdc42 with HA-JNK stimulated kinase activity (Figure 6, A and B). Cotransfection of cells with wild-type SPEC1 significantly reduced the Cdc42-induced JNK activation (Figure 6, A and B). In contrast, SPEC1-P33A,H38A,H41A or SPEC1-Q62A,K66A were markedly less effective at blocking Cdc42-induced JNK activation (Figure 6, A and B). In addition, a similar failure to block Cdc42-induced JNK activation was also observed with the single CRIB domain mutant (data not shown). Although we cannot rule out the possibility that our overexpression studies have resulted in abnormally high levels of SPEC1, which may non-specifically inhibit Cdc42 signaling pathways, these results may also suggest that SPEC1 modulates JNK activity by binding or sequestering Cdc42 through a CRIB-dependent interaction.

Specific Aim 3: We will test the hypothesis that the levels of SPEC1 and SPEC1- $\beta$  proteins in different breast cancer cell lines correlate with breast cancer aggressiveness.

#### Results for Specific Aim 3:

Our preliminary data suggested that only highly metastatic breast cancer cell lines expressed the SPEC1- $\beta$  mRNA. Thus, SPEC1- $\beta$  protein expression may be a marker of highly metastatic breast cancer cells. In order to test this possibility we first performed Northern blot analysis of SPEC1 to examine its expression in a variety of tissues. Using Northern blot analysis with a probe derived from the 3'-untranslated region of the 1.2 kb SPEC1 cDNA (Pirone et al., 2000), we detected the ubiquitous expression of three major transcripts of 1.6, 3.3, and 6.3 kb in brain, uterus, placenta, kidney, spleen and lung (Figure 7A). In these tissues a minor transcript of 10.2 kb was also detected (Figure 7A). To rule out non-specific hybridization, a second probe directed against the 5'-untranslated region of SPEC1 was used in a matched blot. Hybridization with this alternate probe showed an identical distribution pattern to that seen with the 3'-untranslated probe (Figure 7B). Northern analysis using a probe derived from the coding region of SPEC1 also detected the same pattern of mRNA transcripts (data not shown). This Northern data suggests that the different sized SPEC1 mRNA transcripts are derived from alternative splicing. Furthermore, the Northern results seen with the three independent probes demonstrate that the 1.6 kb, 3.3 and 6.3 kb mRNA transcripts all share the originally determined 1.2 kb SPEC1 cDNA sequence.




Figure 7: Northern analysis of SPEC1

In an effort to identify the larger SPEC1 mRNA species, we searched the EST database for cDNA clones that overlapped the previously determined 1.2 kb cDNA sequence of SPEC1. Identification and sequencing of several new overlapping SPEC1 cDNA clones revealed an additional 1.8 kb of 3'-untranslated sequence that contained no additional open reading frames. Sequence analysis of several different SPEC1 cDNA clones revealed that they utilized one of two different polyadenylation signals; one located at nucleotides 1282-1286 and the other at nucleotides 2987-2991 (Figure 8). These results support the data from the SPEC1 Northern



analysis and confirm that the 1.6 kb and 3.3 kb SPEC1 mRNA species are due to alternate usage of these polyadenylation sites.

```

1  CAGAGCTAGCCCCGGAAGCCACACTGGCGGCCACGGAGCAGAGTCCCTCACCCCCACAGCTGTAGCTGAACGCTCGGATGGTGGAGAA
91  GAGCAGGGTTCGAGTCTGAGGAAGACATAACCTTGTGCTGCTGCCACCTCTCTCTGGTCTCTTCATCTCTCAGGCTCTGAGAC
181  ACTGACCTTCACTGCTCAGTTAAAGGTTCCAGGGATTCCACTTTGTCTGGACCCATCCAGCTGAGTGAACCCAGGGTGGTGGTATCTG
271  GGGAGAGTGAGAGTGGGTGTGCCAACACAGGGAAGAGCCCTTTGGGGCTCAGACAGAGGAGTGAAGCTGGAACCATCAGGGAACA
M 1
361  TGAGTGAATTTTGGCACAACCTGGGCTGCTGTGTGGTAGAGAAACCCAGCCGAAGAAGAAGAGAAGACGGATTGACCGGACCATGATTG
S E F W H K L G C C V V E K P Q P K K K R R R I D R T M I G 31
451  GGGAAACCAATGAATTTTGTTCACCTGACTCAGATTGGCTCAGGGGAGATGGAGCTTGGCATGACAGGTGCAAGTTCAGAG
E P M N F V H L T H I G S G E M G A G D G L A M T G A V Q E 61
541  AGCAGATGAGATCCAGGGAAACCGAGATAGGCCATGGAGCAATCTAGGGGCTTAGCTCCAATAATGGAATGGTTCTGCCATCTTGA
Q M R S K G N R D R P W S N S R G L * 79
631  AACCCCCATTCTGTTTCCAGCCAGAAGAAATGCTGCCCTACCAGATCCCTCCTTGAACAGTGATCTAAGGACCCCTCTTTTCCCTAT
721  CTGCCCTAACAGTGCCTCACAAGGCTTGGGGGCTGGACTCCCTCTACTCCCTCTGGCCATAGCCCCCTCTGGAGATGGGGTCAAGGCAGCA
811  GGACTGATCAAGTACTGCTTGGTCCAGAGGGAGCGCTGAAGCCTAGGAAACCCCTCAGGTCTGAGATAGGAGTTCTCTAGGAACCTGG
901  AATGAGTCTCTGCTCCTGAATGATGGTCTGGGTGCCACCTGTTTTAACTCTTAAACCTGGAACCTCTTAAATGGGTAGGTGGGTGA
991  GATTATCAAAGCTGAAGCTGGCTTTGCTGAGAAGCTCCCTACCTCCCTGCCCCTCTCTCTCTCTGGCTGGGAATGAACCTAAAGCAGAT
1081  GTCTAAGCAGGGGCTGGGGGCTGCCCTACTCCCTTTTCCACTCTATCTTTAGATTTCAAACCTTAGGCTTACAGCCCTCAATATCTCTCT
1171  GCTAACACCAGTGTCTCTTTCTAGTTAGGCTCTAATCTTCTGTTTCTGTTTACCAGCTTCCCAGCAACTTTTCTTTTAAATATATTA
1261  AAATTTAATTCAGGTCTCTTAAATATCTCTATCTCTGCTGTTTCCCTCCGCCCTTAACTCTATCCCTATTAGGAACCTTGTTCCTCCACCGAA
1351  TAAGAGTTAAGGTAAGGTAAGTCTCTTACCTGATGACATCCATTTAAGTTTGGGGCATCTTTCCTGCCCTCTGCCAACCTCCCTGCT
1441  GGCCAGGTGAGAGGAGGAAGAGGGGCTTGGAAAGAAACCCAGAATGCCGCGAGAATAGGAGTAAGTCCATCTCAAGTGGACTTCTGAT
1531  CATTTAGGATGGTGAAGATAAATAGGTTGAAAACATCATCTGTGAGTTTAGGAGTCTTAAGATCTCACAGCACGGGAGCAGGGAGAGGC
1621  TCTAGAACCAAGGTTTACACACCGAGATGCCTTTGACATTTGGGCTGAAGTGTCTTTGTAAGGAAACCTGTTTCTTATTTGTGCAATT
1711  ACAGGATATTTAGCAGCAGCCTGGCCACTCTAGTTATGACAAACAAATGTCTCTATACATTGCCAGATTTCTCTAGGGGGCAAAA
1801  TCGCCTCCATTGAGACTACAACCTCTGAGTTCCTGAGGGGGCAAAATCGCCTCCATTGAGAACCCACAACCTCTAAAGTCAAGATATTTT
1891  CTCTGAAGTATTTCTGCTTGGCAGCTACCCCTCATCTACTCTTAAGCCCGAGCATGGATCAACTAGGAGCCCATATAAATGA
1981  GGCTCAGTAGGGCTGACATAATCTCCAAACAATTTCTTAATTCAGTGTATTGCTTGGTGTGTCATGTTGCTATGATTGGAACAAGGTC
2071  CCCCTCTCCATTCTTGCCCTCTGGAGAAGTGGTTCCTGCGAGTGTAGAGATATGAACAGGGTATGGTAGGATTTGGGGAAGGGGAGAG
2161  AAGCAGTAGATACACTCCTTATCCTCCCAAAATTTTAAGCTCTATTTTGTGCCCTAGTCTTAGACACACATTAGACTCAGGGAGTTTGT
2251  TCTGAAGACCAGTCCCACTGCCCCCTGGCTGAAGAGTCTGCTTTAAATGGGAAACACAGTAGGAGCAGGGGTTTTAGGCAGTTTCAG
2341  TTTTCTCAGGTGTTCTGCTTCTGGCCCTTCCAGGGTAATTAGGAAGCAGAACAGACAGATGAGTCTCTGCTGCTGAGACAAGAA
2431  GGGTGGGGTCTCATTAGCTTTGCAACAGGAACATCCTGTTTTATTATGTTAGTGGGGTCAAGAAATGTAGGAACCTGGTATCCATCTGCC
2521  AATTCACCCCACTTCACTTTGCTTATCCCTACAGAACAGTGAAGTTCCTTTTTTTTTTTTTTTTTTTTTTTTCAAAATTCAT
2611  GTATTTTCTGCCATTTTTCAGGGTCTAAGATTGGTCATACATTTCCCAATTTACTCTCAGTTCAGTCAAGCTGGTGTCTGAAAGTAAC
2701  CCAGCTTGTGCTCTAAAATACCTCAGTAGCCTGAGTGTATTAAGAGATCTAAAGGGTTAACAGGATAGGGTGGAAAGGTTAGAGACT
2791  CCTAGAAATCTCTGGTACCCGTGATCTTCGGCTCATTTAATACCTGTTCTTTGGACAGTCTTTTCTTTTGGTGTCTCTTGCTTTA
2881  GCTACCTTCTCTAATATGATGCTACCATCACTAATAAGAGTATGGGAATGGGTTTGAAGTCTGTAATTTATATTAAGGTTGTGGAG
2971  TTTTAAATACATTTTTCAAAATAAAAAATTAAGCAAAAT

```

Figure 8: Nucleotide and amino acid sequences of the human SPEC1 cDNA

In addition to the 3'-end alternatively spliced SPEC1 clones, we also verified the sequence of the SPEC1- $\beta$  splice variant. If translated, the SPEC1- $\beta$  translation product would encode a 38 amino acid protein, in which the first 18 amino acids would be identical to SPEC1 (Figure 9A). SPEC1- $\beta$  would also contain a unique proline rich C-terminus, ending in a CAAX box-like sequence (Figure 9A). Specifically the C-terminal, C-A-V-R sequence of SPEC1- $\beta$  may be involved in plasma membrane targeting as in other proteins such as Ras (Hancock et al., 1991; Moores et al., 1991).

To examine the distribution of the SPEC1- $\beta$  mRNA transcript, we performed RT-PCR with human cDNAs derived from lung, placenta, heart, kidney, liver, and colon. In these experiments, we used two different sets of primers to amplify either the SPEC1 or SPEC1- $\beta$  cDNAs. Using RT-PCR, we obtained the expected 230 bp fragment corresponding to SPEC1 in all tissues examined (Figure 9B). In the case of SPEC1- $\beta$  detection, we designed primers spanning intron 3 to differentiate between the SPEC1- $\beta$  cDNA and potential genomic contamination. Using these SPEC1- $\beta$ -specific primers, a 720 bp fragment corresponding to the SPEC1- $\beta$  cDNA was amplified in all of the same tissues (Figure 9B). In each case, SPEC1 and SPEC1- $\beta$  products were confirmed using Southern blotting (data not





Figure 9: Protein sequence and expression of SPEC1- $\beta$


shown). Based on experiments using primers common to both SPEC1 and SPEC1- $\beta$ , we consistently observed a much lower level of SPEC1- $\beta$  expression as compared to SPEC1 (data not shown). These results confirm the presence of SPEC1- $\beta$ , but suggest that it is present only as a minor transcript.

Because of the unusually small size of the SPEC1- $\beta$  mRNA transcript, we used *in vitro* transcription/translation to examine whether the SPEC1- $\beta$  cDNA could generate a protein product. In these experiments, plasmid constructs were generated containing SPEC1 or SPEC1- $\beta$  cDNAs downstream of the T7 promoter. In this *in vitro* transcription/translation system, the incorporation of biotinylated lysine residues was used to monitor protein production. Analysis of the translation products on an 18% SDS-PAGE gel revealed that SPEC1 and SPEC1- $\beta$  generated 8 and 4 kDa protein species, respectively (Figure 9C). In contrast, no protein product was observed with the sample containing no DNA or with the empty vector control (Figure 9C). These results support the possibility that the SPEC1- $\beta$  protein is translated *in vivo*.

To further understand the organization of the SPEC1 gene and the origin of the mRNA splice variants, a single BAC clone was isolated from a genomic library with a SPEC1-specific probe. While this work was in progress, the working draft sequences of a bacterial artificial chromosome clone (RP11-316M1) containing the SPEC1 gene became available through the Human Genome Project and we have used these data in conjunction with our sequence data to determine the exon-intron organization of the SPEC1 gene. Characterization of the SPEC1 BAC clone by DNA sequencing and PCR



analysis revealed that both the entire 1.6 kb and 3.3 kb SPEC1 cDNAs were encoded by six exons (Figure 10). Of these 6 exons, only exons 2, 3 and 4 encoded the 79 amino acid residues of the SPEC1 protein. Exon 2, consisting of 320 base pairs, contained the start methionine and the first 18 amino acids of the SPEC1 coding sequence (Figure 10). Exon 3 was 111 base pairs and encoded the entire CRIB domain responsible for Cdc42 binding, while exon 4 encoded the C-terminal 24 amino acids of SPEC1 and was 93 base pairs long (Figure 10). The difference in the 3'-ends of the 1.6 kb and 3.3 kb species was due to alternative splicing in exon 6, whereby an additional 1.8 kb of 3'-untranslated sequence generates the 3.3 kb cDNA. We also compared the SPEC1- $\beta$  cDNA sequence with the genomic sequence of SPEC1 to formally prove that the SPEC1- $\beta$  cDNA was derived from the SPEC1 gene. Comparison of these sequences revealed that the 0.5 kb intron located between coding exons 2 and 3 was retained in the SPEC1- $\beta$  cDNA, although other introns in the SPEC1 gene were properly spliced (Figure 10). Finally, using fluorescent *in situ* hybridization the SPEC1 gene was localized to human chromosome 1q21.1-1q21.3, consistent with the sequence and mapping data of the human genome project (data not shown).



To address whether there were differences in the various SPEC1 mRNA transcripts in breast cancer cells, we performed a northern blot using RNA from a panel of breast cancer cell lines, where the cell lines represented were placed in order of increasing metastatic aggressiveness and decreasing ER status (Figure 11). Also included in this panel were three ovarian cancer cell lines on the far right. In this blot, the predominant SPEC1 mRNA species appears to be the 3.3 kb mRNA species and interestingly, while the smaller 1.2 kb mRNA species appears to have a more variable expression pattern. Interestingly, the SPEC1 message may decrease with increasing

metastatic aggressiveness, which may suggest that loss SPEC1 mRNA expression correlates with increased metastatic aggressiveness (Figure 11).



**Key Research Accomplishments**

- We have tested the hypothesis that SPEC1 and SPEC1- $\beta$  proteins affect actin organization and cell shape. In NIH-3T3 fibroblasts we have found that SPEC1 induces the formation of plasma membrane blebbing that was not associated with apoptosis. Furthermore, we have shown that SPEC1 expression alters Cdc42 activity in both Cos1 cells and in NIH-3T3 fibroblasts and that an intact CRIB domain is required for this effect.
- We have examined the effect of SPEC1 on the JNK signaling pathway. In these experiments we have determined that SPEC1 expression does not stimulate JNK activity on its own and when co-expressed with Cdc42, SPEC1 significantly reduced Cdc42-induced JNK activation. This ability of SPEC1 to downregulate JNK activity required both an intact CRIB domain and C-terminus, as mutations in these regions were less effective and blocking Cdc42-induced JNK activation.
- Using Northern blot analysis, we have determined that the SPEC1 mRNA is ubiquitously expressed and is present in multiple molecular weight species of 1.3, 3.3, 6.3, and 10.2 kb, suggesting complex alternative splicing.
- We have determined that the 1.2 kb and 3.3kb molecular weight transcripts of SPEC1 differ in their 3'-untranslated regions and arise via alternate polyadenylation.
- In addition to the 3'-end alternatively spliced SPEC1 clones, we also verified the sequence of the SPEC1- $\beta$  splice variant and examined its distribution by RT-PCR in several human tissues including lung, placenta, heart, kidney, liver, and colon. In these experiments, we detected both SPEC1 and SPEC1- $\beta$  transcripts in each tissue examined, however, we consistently observed a much lower level of SPEC1- $\beta$  expression as compared to SPEC1, suggesting that SPEC1- $\beta$  may be present as only a minor transcript.
- We have determined the genomic sequence of the SPEC1 gene and have found that it is composed of six exons of which exons 2, 3, and 4 contribute to the coding sequence of the SPEC1 protein.
- Comparison of the SPEC1- $\beta$  cDNA sequence with the SPEC1 genomic sequence revealed that SPEC1- $\beta$  was generated by an intron read-through event.
- To address whether there were differences in the various SPEC1 mRNA transcripts in breast cancer cells, we used Northern blotting with RNA from a panel of breast cancer cell lines. In this experiment, we found that the predominant SPEC1 mRNA species appears to be 3.3 kb and that the SPEC1 message may decrease with increasing metastatic aggressiveness.

## **Reportable Outcomes**

### **Publications**

1. **Pirone, D.M.**, Fukuhara, S., Gutkind, J.S., Burbelo, P.D. (2000) SPECS, small binding proteins for Cdc42. *J. Biol. Chem.* 275: 22650-22656.
2. **Pirone, D.M.**, Carter, D.E., Burbelo, P.D. (2001) Evolutionary expansion of CRIB-containing Cdc42 effector proteins. *Trends in Genetics* 17: 370-373.
3. **Pirone, D.M.**, Oberst, M.D., Carter, D.E., and Burbelo, P.D. (2001) The genomic structure of the human SPEC1 gene reveals complex splicing and close promoter proximity to the AF1q translocation gene. *Gene* 273(2): 295-303.

### **Abstracts**

1. **Pirone, D.**, Fukuhara, S., Gutkind, S., Burbelo, P. Small Binding Proteins Regulate Cdc42 Signaling. (abstract for 91<sup>st</sup> American Association for Cancer Research annual meeting)
2. **Pirone, D.**, Oberst, M., and Burbelo, P. Potential role of SPEC1 as a Cdc42 adapter molecule involved in integrin assembly and signaling. (abstract for 92<sup>nd</sup> American Association for Cancer Research annual meeting)

### **Honors or Awards**

- |      |  |
|------|--|
| 2001 | Second Place Award in Georgetown University Student Research Days Poster Competition |
| 2001 | Finalist in Lombardi Cancer Center Research Fair                                     |
| 2000 | First Place Award in Lombardi Cancer Center Research Fair                            |

### **Invited seminars on research topic**

- |               |  |
|---------------|--|
| February 2001 | Mount St. Marys College, Emmitsburg, MD. "Control of the cytoskeleton by Cdc42 signaling pathways"   |
| March 2001    | Georgetown University, Student Research Days Oral Competition. "Potential role of SPEC1 as a Cdc42 adapter molecule involved in integrin assembly and signaling"   |
| March 2001    | Laboratory of Craniofacial Developmental Biology and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD. "Role of SPECS in Cdc42 signaling pathways" |
| May 2001      | Yale University School of Medicine, Department of Internal Medicine Section of Medical Oncology, New Haven, CT. "Functional analysis of the SPEC family of proteins and their role in Cdc42 signaling pathways."           |
| August 2001   | Johns Hopkins University School of Medicine, Department of Biomedical Engineering, Baltimore, MD. "SPEC1: a link between Cdc42 and integrins?"   |

### **Degrees obtained when supported by this award**

Ph.D. in Tumor Biology from Georgetown University

### **Employment received based on experience/training supported by this award**

Post-doctoral fellowship position received from Johns Hopkins University in the Biomedical Engineering Department

### Conclusions

To date, we have made significant progress on the specific aims set forth in the research proposal. First, we have addressed whether SPEC1 and SPEC1- $\beta$  proteins affect actin organization and cell shape. From these studies, we have determined that in NIH-3T3 fibroblasts, SPEC1 induces the formation of plasma membrane blebbing that was not associated with apoptosis. Mechanistically, membrane blebs occur at sites where the cortical actin is locally depolymerized or detached from the membrane (Cunningham, 1995; Keller and Eggli, 1998, Cunningham et al., 1992) via alteration in cortical actin-binding proteins (Keller and Eggli, 1998), myosin light chain kinase activity (Mills et al., 1998; Huot et al., 1998) and/or focal complex assembly (Huot et al., 1998). It is likely that SPECs function as classical Cdc42 effector proteins by altering the normal signaling pathways leading to actin, myosin, and/or focal complex assembly. Furthermore, we have shown that SPEC1 expression alters Cdc42 activity in both Cos1 cells and in NIH-3T3 fibroblasts and that an intact CRIB domain is required for this effect. SPEC1 also affects the JNK signaling pathway, where SPEC overexpression significantly reduced Cdc42-induced JNK activation. This ability of SPEC1 to downregulate JNK activity required both an intact CRIB domain and C-terminus, as mutations in these regions were less effective and blocking Cdc42-induced JNK activation. Together, these results show that SPECs are capable of modifying Cdc42-dependent signaling at both the biochemical and cellular levels.

We have also examined the mRNA distribution pattern of SPEC1. Using Northern blot analysis, we have determined that the SPEC1 mRNA is ubiquitously expressed and is present in multiple molecular weight species of 1.3, 3.3, 6.3, and 10.2 kb, suggesting complex alternative splicing. For at least two of the molecular weight species, the SPEC1 mRNA transcripts differ in their 3'-untranslated regions. Although the functional consequences of these different 3'-end mRNAs are not known, they may show altered stability or cellular localization. In addition to the alternative splicing in the 3'-end of the SPEC1 mRNA, there is also a SPEC1 splice variant from within the SPEC1 coding sequence, SPEC1- $\beta$ . SPEC1- $\beta$ , was detected by RT-PCR as a minor transcript in a variety of human tissues. Interestingly, the mechanism by which the SPEC1- $\beta$  mRNA transcript is produced involves intron retention. Intron retention occurs in other genes and frequently occurs in cancer. For instance, there is an aberrant inclusion of intron 9 in CD44 transcripts in tumor tissues, including bladder cancer, breast cancer, ovarian cancer, and gastrointestinal tumors (Matsumura et al., 1995; Yoshida et al., 1995; Bolodeoku et al., 1996). Although SPEC1- $\beta$  is present at low levels in a variety of normal tissues, it is possible that this isoform may occur more frequently in tumor tissues. Experiments using *in vitro* translation confirmed that the SPEC1- $\beta$  cDNA generates the expected 3.8 kDa protein product. Since the SPEC1- $\beta$  protein lacks a CRIB domain involved in Cdc42 binding and contains a potential membrane targeting sequence, it may function as a signaling molecule independent of Cdc42 control. Taken together, these results suggest the possibility that the SPEC1- $\beta$  protein may exist *in vivo* and may have its own unique biological activities. An additional potentially exciting result is that SPEC1 mRNA expression appears to correlate with metastatic aggressiveness, where more highly aggressive cell lines apparently lose SPEC1 mRNA expression. In preliminary experiments examining the protein levels of SPEC1 in a panel of breast cancer cell lines of increasing metastatic aggressiveness, there appeared to be a variable expression of SPEC1 protein (data not shown), however these results await future validation.

## References

- Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, Siminovitch KA, Rosen MK. 1999. Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein. *Nature* 399(6734):379-383.
- Bagrodia S, Derijard B, Davis RJ, Cerione RA. 1995. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. *J. Biol. Chem.* 270(47):27995-27998.
- Bolodeoku J, Yoshida K, Sugino T, Goodison S, Tarin D. 1996. Accumulation of immature intron-containing CD44 gene transcripts in breast cancer tissues. *Mol. Diagn.* 1:175-181.
- Braga VM, Machesky LM, Hall A, Hotchin NA. 1997. The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts. *J. Cell Biol.* 137(6):1421-1431.
- Brown JL, Stowers L, Baer M, Trejo J, Coughlin S, Chant J. 1996. Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. *Curr. Biol.* 6(5):598-605.
- Burbelo PD, Drechsel D, Hall A. 1995. A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. *J. Biol. Chem.* 270(49):29071-29074.
- Burbelo PD, Snow DM, Bahou W, Spiegel S. 1999. MSE55, a Cdc42 effector protein, induces long cellular extensions in fibroblasts. *Proc. Natl. Acad. Sci. USA* 96(16):9083-9088.
- Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. 1995. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. *Cell* 81(7):1137-1146.
- Cunningham CC, Gorlin JB, Kwiatkowski DJ, Hartwig JH, Janmey PA, Byers HR, Stossel TP. 1992. Actin-binding protein requirement for cortical stability and efficient locomotion. *Science* 255(5042):325-327.
- Cunningham CC. 1995. Actin polymerization and intracellular solvent flow in cell surface blebbing. *J. Cell Biol.* 129(6):1589-1599.
- Erickson CA, Trinkaus JP. 1976. Microvilli and blebs as sources of reserve surface membrane during cell spreading. *Exp. Cell Res.* 99(2):375-384.
- Fidler IJ, Gersten DM, and Hart IR. 1978. The biology of cancer invasion and metastasis. *Advanc. Cancer Res.* 28: 149-154.
- Hancock JF, Cadwallader K, Paterson H, Marshall CJ. 1991. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. *EMBO J.* 10: 4033-4039.
- Higgs HN, Pollard TD. 1999. Regulation of actin polymerization by Arp2/3 complex and WASp/Scar proteins. *J. Biol. Chem.* 274(46):32531-32534.
- Huot J, Houle F, Rousseau S, Deschesnes RG, Shah GM, Landry J. 1998. SAPK2/p38-dependent F-actin reorganization regulates early membrane blebbing during stress-induced apoptosis. *J. Cell Biol.* 143(5):1361-1373.

- Keller H, Eggli P. 1998. Protrusive activity, cytoplasmic compartmentalization, and restriction rings in locomoting blebbing Walker carcinosarcoma cells are related to detachment of cortical actin from the plasma membrane. *Cell Motil. Cytoskeleton* 41(2):181-193.
- Kozma R, Ahmed S, Best A, Lim L. 1995. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. *Mol. Cell Biol.* 15(4):1942-1952.
- Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. 2000. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. *Cell* 102(3):387-397.
- Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, Lim L. 1997. Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. *Mol. Cell Biol.* 17(3):1129-1143.
- Martin G, Bollag F, McCormick F, Abo A. 1995. A novel serine kinase activated by Rac/Cdc42Hs-dependent phosphorylation is related to PAK65 and Ste20. *EMBO J.* 14: 1970-1978.
- Matsumura Y, Sugiyama M, Matsumura S, Hayle A, Robinson P, Smith J, Tarin D. 1995. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. *J. Pathol.* 177:11-20.
- Miki H, Miura K, Takenawa T. 1996. N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. *EMBO J.* 15(19):5326-5335.
- Mills JC, Stone NL, Erhardt J, Pittman RN. 1998. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. *J. Cell Biol.* 140(3):627-636.
- Minden A, Lin A, Claret FX, Abo A, Karin M. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. *Cell* 81(7):1147-1157.
- Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL, Gibbs JB. 1991. Sequence dependence of protein isoprenylation. *J. Biol. Chem.* 266: 14603-14610.
- Mott HR, Owen D, Nietlispach D, Lowe PN, Manser E, Lim L, Laue ED. 1999. Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK. *Nature* 399(6734):384-388.
- Nobes CD, Hall A. 1995. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. *Cell* 81(1):53-62.
- Nobes CD, Hall A. 1999. Rho GTPases control polarity, protrusion, and adhesion during cell movement. *J. Cell Biol.* 144(6):1235-1244.
- Nur-E-Kamal MS, Kamal JM, Qureshi MM, Maruta H. 1999. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. *Oncogene* 18(54):7787-7793.
- Osada S, Izawa M, Koyama T, Hirai S, Ohno S. 1997. A domain containing the Cdc42/Rac interactive binding (CRIB) region of p65PAK inhibits transcriptional activation and cell transformation mediated by the Ras-Rac pathway. *FEBS Lett.* 404(2-3):227-233.

- Pirone DM, Fukuhara S, Gutkind JS, Burbelo PD. 2000. SPECS, small binding proteins for Cdc42. *J. Biol. Chem.* 275(30):22650-22656.
- Prehoda KE, Scott JA, Mullins RD, Lim WA. 2000. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. *Science* 290(5492):801-806.
- Qiu RG, Abo A, Steven Martin G. 2000. A human homolog of the *C. elegans* polarity determinant Par-6 links Rac and Cdc42 to PKC $\zeta$  signaling and cell transformation. *Curr. Biol.* 10(12):697-707.
- Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T, Kirschner MW. 1999. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. *Cell* 97(2):221-231.
- Symons M, Derry JM, Karlak B, Jiang S, Lemahieu V, McCormick F, Francke U, Abo A. 1996. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. *Cell* 84(5):723-734.
- Takaishi K, Sasaki T, Kotani H, Nishioka H, Takai Y. 1997. Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. *J. Cell Biol.* 139(4):1047-1059.
- Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS. 1996. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. *J. Biol. Chem.* 271(44):27225-27228.
- Trinkaus JP. 1980. Formation of protrusions of the cell surface during tissue cell movement. *Prog. Clin. Biol. Res.* 41:887-906.
- Van Aelst L, D'Souza-Schorey C. 1997. Rho GTPases and signaling networks. *Genes Dev.* 11(18):2295-2322.
- Yoshida K, Bolodeoku J, Sugino T, Goodison S, Matsumura Y, Warren B, Toge T, Tahara E, Tarin D. 1995. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. *Cancer Res.* 55:4273-4277.
- Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM. 1995. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. *J. Biol. Chem.* 270(41):23934-23936.



## SPECs, Small Binding Proteins for Cdc42\*

Received for publication, April 4, 2000, and in revised form, May 15, 2000  
Published, JBC Papers in Press, May 16, 2000, DOI 10.1074/jbc.M002832200

Dana M. Pirone<sup>‡</sup>, Shigetomo Fukuhara<sup>§</sup>, J. Silvio Gutkind<sup>§</sup>, and Peter D. Burbelo<sup>‡¶</sup>

From the <sup>‡</sup>Lombardi Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, D. C. 20007 and <sup>§</sup>Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892

**The Rho GTPase, Cdc42, regulates a wide variety of cellular activities including actin polymerization, focal complex assembly, and kinase signaling. We have identified a new family of very small Cdc42-binding proteins, designated SPECs (for Small Protein Effector of Cdc42), that modulates these regulatory activities. The two human members, SPEC1 and SPEC2, encode proteins of 79 and 84 amino acids, respectively. Both contain a conserved N-terminal region and a centrally located CRIB (Cdc42/Rac Interactive Binding) domain. Using a yeast two-hybrid system, we found that both SPECs interact strongly with Cdc42, weakly with Rac1, and not at all with RhoA. Transfection analysis revealed that SPEC1 inhibited Cdc42-induced c-Jun N-terminal kinase (JNK) activation in COS1 cells in a manner that required an intact CRIB domain. Immunofluorescence experiments in NIH-3T3 fibroblasts demonstrated that both SPEC1 and SPEC2 showed a cortical localization and induced the formation of cell surface membrane blebs, which was not dependent on Cdc42 activity. Cotransfection experiments demonstrated that SPEC1 altered Cdc42-induced cell shape changes both in COS1 cells and in NIH-3T3 fibroblasts and that this alteration required an intact CRIB domain. These results suggest that SPECs act as novel scaffold molecules to coordinate and/or mediate Cdc42 signaling activities.**

The Rho GTPase, Cdc42, regulates numerous and diverse biological activities at both the biochemical and cellular levels. Cdc42 influences membrane trafficking (1), cytokinesis (2), and kinase signaling pathways, leading to transcriptional activation (3). Cdc42 is best known for controlling the formation of filopodia, thin actin-containing structures that protrude from the cell surface (4, 5). In addition to the direct effect of Cdc42 on filopodia formation, Cdc42 can also induce cross-activation of Rac, leading to membrane ruffling (5). This cross-talk among small GTPases may function to coordinate the formation and dismantling of different cortical actin structures, such as filopodia, ruffles, lamellopodia, and membrane blebs, often seen during cell migration (6).

The ability of Cdc42 to influence these diverse activities

stems from its interactions with a large number of different kinase and non-kinase effector proteins. Although GTP-bound Cdc42 usually interacts with downstream effector proteins containing the conserved binding motif called a CRIB<sup>1</sup> domain (7), some downstream Cdc42 effector proteins such as IQGAP do not contain CRIB domains (8, 9). To date, six distinct families of CRIB domain-containing Cdc42 effector proteins have been identified: PAK (10, 11), MRCK (12), ACK (13), MLK (7, 14), WASP (15, 16) and MSE55/BORG/CEP (17, 18). The first four of these families are kinases. The most extensively studied Cdc42 effector proteins, the PAK kinases (3), participate in the Cdc42-mediated cytoskeleton rearrangements that lead to cell motility (19). PAK kinases also activate the JNK and p38 stress kinase pathways (20–22) and are targets of caspase-mediated proteolytic cleavage during apoptosis (23). MRCK kinases affect actin/myosin reorganization by phosphorylating non-muscle myosin light chain (12). Less is known about the signaling pathways and cellular processes affected by ACK tyrosine kinases, but they may influence cell adhesion signals (24). The fourth family, MLK kinases, play a role in kinesin function and JNK activation (14, 25, 26).

WASP and a related protein, N-WASP, comprise a family of non-kinase CRIB-containing proteins that function in actin polymerization (15, 16). N-WASP regulates filopodia formation by producing free actin filaments either via its cofilin actin-severing domain (16) or through interactions with the actin-severing protein, profilin (27). Both WASP and N-WASP also positively regulate the ARP2/3 protein complex, which stimulates actin nucleation (28, 29). The other non-kinase, CRIB-containing set of Cdc42 effector proteins, is the MSE55/CEP/BORG family, which is the most structurally diverse. This family, consisting of five members, all induce long actin-containing cellular extensions in NIH-3T3 fibroblasts (17, 18).

With so many different Cdc42 effector proteins, many of which may coexist in a single cell, competition and/or some mechanism for coordination must exist to ensure that the proper Cdc42 signal is propagated. Although many individual Cdc42 effector proteins have been studied, little is known about how these effector proteins cooperate and/or compete with each other, either in regulating the cytoskeleton or in kinase signaling. Here, we have identified a novel family of Cdc42 effector proteins that may play a role in this higher level of coordination. This new family, designated SPEC (for Small Protein Effector of Cdc42) has two human members, SPEC1 and SPEC2. Both are very small and are highly conserved. SPECs appear to have multifaceted activities, of which some are independent of Cdc42 binding and some are dependent on Cdc42

\* This work was supported by Susan G. Komen Foundation Grant 9851 (to P. D. B.) and a Department of Defense (DOD) breast cancer pre-doctoral fellowship (to D. M. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) AF187845 and AF189692.

¶ To whom correspondence should be addressed: Rm. EG16, New Research Bldg., Lombardi Cancer Center 3970 Reservoir Rd. NW, Georgetown University Medical Center, Washington, D. C. 20007. Tel.: 202-687-1444; Fax: 202-687-7505; E-mail: burbelpd@gunet.georgetown.edu.

<sup>1</sup> The abbreviations used are: CRIB, Cdc42/Rac interactive binding domain; AKAP, A-kinase anchoring protein; EST, expressed sequence tag; JNK, c-Jun N terminal kinase; SPEC, small protein effector of Cdc42; EGFP, enhanced green fluorescent protein; PCR, polymerase chain reaction; FITC, fluorescein isothiocyanate; contig, group of overlapping clones; HA, hemagglutinin.



binding. For instance, expression of SPECs in NIH-3T3 fibroblasts induced membrane blebbing. SPEC-induced blebbing did not require Cdc42 activity because blebbing still occurred with a CRIB domain mutant of SPEC or in the presence of dominant negative Cdc42. SPEC1 blocked both Cdc42-induced JNK activity and altered Cdc42-induced morphology changes in COS1 cells and in NIH-3T3 fibroblasts in a manner that required an intact CRIB domain and, thus, was dependent on Cdc42 binding. Together these results suggest that SPECs act as novel scaffold molecules to coordinate and/or mediate Cdc42 signaling activities.

#### EXPERIMENTAL PROCEDURES

**Identification and Cloning of SPECs**—Clones of SPEC1 were identified from a TBLASTN search of the expressed sequence tag (EST) data base at the National Center for Biotechnology Information (NCBI) using the 16-amino acid CRIB core sequence of MSE55 (7) (ISHLPLGD-FRHTMHVGR) as a query. Several of these human EST clones were obtained from the I.M.A.G.E. consortium (clone ID numbers: 257442, 139233, 160147) and sequenced on an Applied Biosystem 377 DNA sequencer. The GenBank<sup>®</sup> accession number of SPEC1 is AF187845. Furthermore, EST clones for human and mouse SPEC1 are quite abundant and are represented by the NCBI Unigene identifiers Hs.22065 and Mm.28189, respectively.

Additional TBLASTN searches of the non-redundant nucleotide data base using the amino acid sequence of SPEC1 as query identified three well separated DNA sequences that if transcribed as a single mRNA and properly spliced might encode a second SPEC-like protein. Two adapter-primers, 5'-GAGGGATCCAGTGAATTCTGGTTGTGT-3' and 5'-GAGCTCGAGCTATCCCGCCTTCGTATC-3', derived from these genomic sequences and corresponding to each end of the putative coding sequence, were synthesized. These two primers were used in reverse transcription-PCR with MCF-7 breast cancer cell RNA as template. After PCR, an approximately 250-base pair PCR fragment was obtained, cut with *Bam*HI/*Xho*I, and subcloned into the *Bam*HI-*Xho*I site of pCAF2, a mammalian expression vector (17). DNA sequencing revealed that the nucleotide sequence of this PCR product was, as expected, derived from the three different 5q31 genomic fragments and encodes a protein, designated SPEC2, that was quite similar to SPEC1. SPEC2 has GenBank<sup>®</sup> accession number AF189692.

**Yeast Two-hybrid Assays**—The yeast two-hybrid assay was performed in the Y190 yeast strain using the pYTH GAL4 DNA binding domain yeast vector and pACT-II GAL4 activation domain yeast vectors (30). cDNAs for SPEC1 (amino acids 2–79) or SPEC2 (amino acids 2–84) were subcloned downstream of the GAL4 DNA binding domain in pYTH-9, and integrated strains were generated as described (30). Deletion mutants of SPEC1 consisting of amino acids 2–27 (SPEC1-del1) or amino acids 48–79 (SPEC1-del2) were constructed in the same way. Wild type and activated mutants of Cdc42, Rac, and Rho were subcloned downstream of the GAL4 activation domain in pACT-II. Protein-protein interactions were detected by assaying for  $\beta$ -galactosidase activity in a filter assay or by growth on nutrient agar plates lacking histidine (30).

**Mammalian Expression Vectors for SPEC1, SPEC2, and Mutants**—The coding sequence of SPEC1 was amplified by PCR from the I.M.A.G.E. cDNA clone (ID 22978) using the two primers 5'-GAGGGATCC-AGTGAATTTTGGCACAAC-3' and 5'-GAGCTCGAGCTATAAGCCCTAGAATTG-3'. This PCR product was then subcloned in-frame into the *Bam*HI-*Xho*I sites downstream of an N-terminal myc epitope-tagged pcDNA-III (Invitrogen) or an N-terminal FLAG epitope-tagged pCAF2 mammalian expression vector. An additional C-terminal myc epitope-tagged SPEC1 construct was constructed in the pcDNA-III mammalian expression vector. Untagged SPEC1 constructs were also constructed using the bicistronic enhanced green fluorescent protein (EGFP) vector (CLONTECH). The integrity of all constructs was confirmed by DNA sequencing.

Several SPEC1 mutant constructs were generated from the epitope-tagged constructs by using SPEC1 sequence-specific oligonucleotides and the QuickChange mutagenesis kit (Stratagene). Four single or multiple SPEC1 point mutants containing alanine substitutions in the N terminus (SPEC1-C10A,C11A), the CRIB domain (SPEC1-H38A and SPEC1-P35A,H38A,H41A) or in the C terminus (SPEC1-Q62A,K64A) were constructed. The integrity of all constructs was confirmed by DNA sequencing. All of these mutants and their parent constructs had approximately similar levels of expression in transfected cells as judged by immunofluorescence.

**JNK Kinase Assays**—COS1 cells were used to examine whether SPEC influenced JNK kinase activation using ATF-2 as substrate as described (31). Equal amounts of DNA were used in each transfection.

**Immunofluorescence**—Immunofluorescence of NIH-3T3 fibroblasts was performed essentially as described (17) except that LipofectAMINE Plus (Life Technologies, Inc.) was used as the transfection reagent. Twenty-four hours post-transfection, NIH-3T3 fibroblasts were fixed and permeabilized on glass coverslips coated with polylysine. Coverslips were stained with the myc and FLAG anti-epitope primary antibodies including mouse anti-FLAG<sup>®</sup> M2 (Sigma), mouse anti-c-myc monoclonal antibody (Sigma), and polyclonal anti-FLAG<sup>®</sup>/Octaprobe antibody (Santa Cruz Biotechnology). Fluorescein-conjugated goat anti-mouse IgG (Rockland Immunochemicals, Gilbertsville, PA), Texas Red anti-mouse (Jackson ImmunoResearch Laboratories, Inc.), and FITC-conjugated goat-anti-rabbit (Rockland Immunochemicals) were used as secondary antibodies. Texas Red-conjugated Phalloidin (Sigma) was used to stain F-actin. Nuclear and phosphatidylserine staining was also performed using 4,6-diamidino-2-phenylindole (Sigma) and annexin-V (Trivigen, Inc.), respectively.

Blebbing cells were quantified in vector alone and in SPEC-transfected cells 24 h post-transfection. Cells with two or more outpouchings were scored as positive for membrane blebbing. Fifty to one hundred cells were scored from each of at least three independent transfections. A Zeiss Photomicroscope III equipped with a Planapo 63X/1.4 NA phase 3 objective was used, and photographs were taken with Kodak TMAX400 film using a Nikon N6006 camera.

#### RESULTS

**Identification of Genes for SPEC1 and SPEC2**—Most known Cdc42-binding proteins contain a conserved core domain, the CRIB domain (7). We looked for additional proteins that might bind Cdc42 by searching the human EST data base for sequences similar to the CRIB domain of the non-kinase Cdc42 effector protein MSE55/CEP1 (17) and identified many cDNAs encoding the same small protein. The DNA sequences of several independent human clones comprising a contig spanning 1.8 kilobases each showed an open reading frame of 79 amino acid residues, which we designated SPEC1 (Fig. 1). These cDNAs encoding the SPEC1 protein contained a Kozak consensus sequence and an upstream in-frame stop codon and did not encode any proteins longer than SPEC1. A second human SPEC family member, designated SPEC2, was identified by searching the non-redundant GenBank<sup>™</sup> data base. This search identified three short separated genomic regions from chromosome 5q31, spanning at least 28 kilobases (GenBank<sup>™</sup> accession numbers AC001489 and AC001223) that if transcribed and properly spliced would encode a second SPEC-like protein. To clone the SPEC2 cDNA sequence, primers were designed for the two extreme ends of the genomic regions and used in reverse transcription-PCR. This approach yielded a 250-base pair PCR fragment containing an open reading frame of 84 amino acids (Fig. 1). Comparison of this sequence with 5q31 genomic sequences confirmed that the full-length SPEC2 protein was encoded in three exons spanning at least 28 kilobases.

In addition to the human SPEC1 and SPEC2 proteins, we have also identified both SPEC1 and SPEC2 homologs in other organisms. We have identified SPEC1 homologs from mouse (GenBank<sup>™</sup> AI472516) and chicken (GenBank<sup>™</sup> AI981286) that are 96 and 83% identical to SPEC1 at the amino acid level, respectively (Fig. 1). We have also identified SPEC2 homologs from mouse (GenBank<sup>™</sup> AW061198), rat (GenBank<sup>™</sup> AA944330), *Drosophila* (AA820736), and ascidian (*Halocynthia roretzi*; GenBank<sup>™</sup> AV382466) (Fig. 1). Identification of the SPEC proteins in such diverse organisms suggests their function may be conserved through evolution.

**SPECs Represent a Novel Family of Cdc42-binding Proteins**—SPEC1 and SPEC2 represent two members of a new protein family that are 76% similar over their entire length (Fig. 1) and encode proteins with predicted molecular masses of 7.9 kDa and 8.4 kDa, respectively. Both SPECs contain a

**Fig. 1. The SPEC protein family.** Alignment of full-length human SPEC1 and SPEC2 amino acid sequences. ESTs corresponding to mouse SPEC1 (AI472516), chicken SPEC1 (AI981286), and *Xenopus* SPEC2 (AW644132) and *Drosophila* SPEC2 (AAF51990) are also shown. Vertical lines identify identical residues, colons represent conservative substitutions, and the numbers at the ends represent the total number of amino acid residues. The CRIB consensus is shown (7), and sequences matching this consensus sequence are shown in **bold letters**. Human SPEC1 and SPEC2 sequences are available from GenBank™ under accession numbers AF187845 and AF189692, respectively.

		CRIB consensus = <b>ISXFXFXEXXHV</b> G
mouse SPEC1	MSEFWHLGCVVEKPPKKRR---RIDRTMIGEPN <b>FVHLTH</b> IGSGEMGAGDGLAM	
chicken SPEC1	MSDFWHLGCVVEKPPKKRR---RIDRTMIGEPN <b>FVHLTH</b> IGSGDMAAGEGLPM	
human SPEC1	MSEFWHLGCVVEKPPKKRR---RIDRTMIGEPN <b>FVHLTH</b> IGSGEMGAGDGLAM	
human SPEC2	MSEFWLCNCCIAEQPPK---RIDRTMIGEPN <b>FVHTAH</b> VGSGDLFGSMNSVS	
<i>Xenopus</i> SPEC2	MTEFLFCFSCCIGEQPPK---RIDRTMIGEPN <b>FVHTAH</b> VGSGDITNAGFAMGG	
<i>Drosophila</i> SPEC2	MASTGEIWLQWFSCCFQQQSPSRPHQRLRIDRTMIGEPN <b>FVHTAH</b> IGSADVELSANRLN	
mouse SPEC1	TGAVQEQMRSGKNHRDPWSNSRAL* 80	
chicken SPEC1	TGAVQE-MRSKGG-RERQWSSSRVL* 78	
human SPEC1	TGAVQEQMRSGKN-RDRPWSNSRGL* 79	
human SPEC2	SI--QNQMCKSGGYGGMPANVQMQLVDTKAG* 84	
<i>Xenopus</i> SPEC2	SF--QDMKSKGGYTPGISEVAL* 75	
<i>Drosophila</i> SPEC2	AIST--QMCKSGGCTNSIHLHVS* 84	

highly conserved N-terminal region and a typical CRIB domain. The CRIB domains of the SPECs extend beyond the CRIB core sequence and contain the consensus sequence DR(S/T)MIGEPXN**FVHXXH**AGSGD/EAXXG, where A represents an aliphatic amino acid, and bold letters identify the CRIB core (Fig. 1). In the C terminus of both proteins there is a relatively small conserved sequence containing the nine-amino acid consensus sequence, (V/I)Q(E/N)QM(R/Q)SKG (Fig. 1). This region may be part of an extended high affinity Cdc42 binding site (32, 33).

**CRIB-dependent Cdc42 Binding by SPECs**—Since proteins containing a consensus CRIB domain will bind Cdc42 and/or Rac (7), we predicted that both SPEC1 and SPEC2 also would interact with Cdc42 and/or Rac. We tested this prediction in a yeast two-hybrid system. Both SPEC1 and SPEC2 interacted strongly with a constitutively activated mutant of Cdc42 (Cdc42-Q61L), weakly with an activated mutant of Rac1 (Rac1-Q61L), and not at all with an activated mutant of RhoA (RhoA-Q63L) using both the  $\beta$ -galactosidase filter assay (Fig. 2) and growth on selective media (data not shown). Although interaction of SPECs with wild type Cdc42 and wild type Rac1 was not observed, our results are consistent with yeast two-hybrid experiments using other CRIB-containing Cdc42 effector proteins, such as WASP (30). Additionally, SPEC CRIB deletion mutants retaining either the N terminus (SPEC1-del1; amino acids 2–27) or the C terminus (SPEC1-del2; amino acids 48–79) were unable to bind to an activated Cdc42 mutant (Fig. 2). Collectively, these results demonstrate that SPECs can interact with Cdc42 in a CRIB-dependent fashion and suggest that SPECs may function normally in Cdc42-dependent signaling.

**SPEC1 Expression Inhibits Cdc42-induced JNK Activity**—Since a variety of studies have shown both that Cdc42 (31, 34) and some Cdc42 effector proteins (14, 20–22, 26) can activate JNK activity, we tested SPEC1 and several SPEC1 mutants for their effect on Cdc42-induced JNK activation. First, an expression construct of human SPEC1 carrying an N-terminal FLAG epitope tag was transfected into NIH-3T3 fibroblasts, and its expression was analyzed by Western blotting using a monoclonal antibody against the N-terminal FLAG epitope tag. Using this approach, SPEC1 was detected in lysates as an ~8 kDa species (data not shown), of which about 1 kilobase is contributed by the epitope tag. Second, several SPEC1 mutants were constructed, including two CRIB mutants and a C-terminal double mutant. The two CRIB mutants, SPEC1-H38A and SPEC1-P33A,H38A,H41A, contain alanine substitutions within critical contact sites known to be involved in Cdc42

binding (33, 34). The third mutant, SPEC1-Q62A,K66A, contained mutations within the nine-amino acid region conserved between both SPEC proteins that might be part of an extended high affinity Cdc42 binding site. COS1 cells were cotransfected with the expression vectors for GFP (control) or Cdc42-Q61L, hemagglutinin (HA) epitope-tagged JNK, and FLAG-tagged SPEC1 constructs. After 24 h, transiently expressed HA-JNK was isolated by immunoprecipitation and used for *in vitro* kinase assays. All SPEC1 constructs tested were not able to stimulate JNK activity on their own (Fig. 3A). Expression of Cdc42 with HA-JNK stimulated kinase activity (Fig. 3, A and B). Cotransfection of cells with wild-type SPEC1 significantly reduced the Cdc42-induced JNK activation (Fig. 3, A and B). In contrast, SPEC1-P33A,H38A,H41A or SPEC1-Q62A,K66A were markedly less effective at blocking Cdc42-induced JNK activation (Fig. 3, A and B). In addition, a similar failure to block Cdc42-induced JNK activation was also observed with the single CRIB domain mutant (data not shown). Although we cannot rule out the possibility that our overexpression studies have resulted in abnormally high levels of SPEC1, which may nonspecifically inhibit Cdc42 signaling pathways, these results may also suggest that SPEC1 modulates JNK activity by binding or sequestering Cdc42 through a CRIB-dependent interaction.

**SPEC1 Expression Inhibits Cdc42-induced Morphological Changes in COS1 Cells**—We next examined the cellular distribution of epitope-tagged SPEC1 expression by immunofluorescence. In COS1 cells, SPEC1 showed diffuse cytoplasmic localization (Fig. 4B). Additionally, SPEC-expressing cells did not show altered actin structures or cell morphology (data not shown). We next determined whether SPEC1 influenced Cdc42 function when co-expressed with Cdc42. COS1 cells expressing the constitutively active Cdc42-Q61L mutant exhibited a widely spread and flattened phenotype with some filopodia (Fig. 4, A and B). Cotransfection of SPEC1 with Cdc42-Q61L resulted in cells that were more elevated and much less spread than cells expressing Cdc42-Q61L alone (compare Fig. 4, C and D with A) or untransfected cells (data not shown). In contrast to what was seen with wild-type SPEC1, cells coexpressing Cdc42-Q61L and the CRIB domain mutant (SPEC1-H38A) resembled cells transfected with Cdc42-Q61L alone (compare Fig. 4, E and F with A). These results suggest that SPEC1 modifies Cdc42 function. In these experiments, SPEC1 appears to alter Cdc42 activity by binding to it via the CRIB domain. These results suggest that SPECs may function to block the interaction of Cdc42 with other effector proteins, although we cannot

	Cdc42	Cdc42-Q61L	Rac1	Rac1-Q61L	RhoA-Q63L
SPEC1	-	+++	-	+	-
SPEC2	-	+++	-	+	-
SPEC1-del1	ND	-	ND	-	-
SPEC1-del2	ND	-	ND	-	-

FIG. 2. SPEC1 and SPEC2 interact with Cdc42 in yeast two-hybrid assays. pYTH9 GAL4-DNA binding constructs were generated for SPEC2, SPEC1, or deletions of SPEC1 and then integrated into Y190 yeast cells. These yeast strains were used as host cells for transformations with pACT-GAL4 activation constructs to test interactions with Rho GTPases. The strength of the interaction was classified by the time taken for colonies to turn blue in the  $\beta$ -galactosidase filter assay: +++, <25 min; ++, 25–50 min; +, 50–100 min; -, no color change by 100 min; and ND, not determined.




FIG. 3. SPEC1 inhibits Cdc42-induced JNK activation. COS1 cells were transfected with expression vectors for GFP (control) or activated Cdc42 mutant (Cdc42-QL61), HA-tagged JNK, and different FLAG-tagged SPEC1 constructs. Following immunoprecipitation, JNK activity was assayed using ATF-2 as substrate (A). Similar results were obtained in three independent experiments. This assay was normalized by Western blot analysis using anti-HA immunoprecipitates from the cellular lysates and immunodetected with JNK antisera as described under "Experimental Procedures." Results are the averages  $\pm$  S.E. of three experiments. WT, wild type.

rule out the possibility that the observed blocking activity was due to overexpression of SPEC1 protein.

**SPEC Expression Induces Non-apoptotic Blebbing in NIH-3T3 Fibroblasts**—Since SPEC1 expression did not noticeably alter the morphology of COS1 cells, we studied the effects of SPEC1 expression in NIH-3T3 fibroblasts. In NIH-3T3 fibroblasts, SPEC1 displayed a predominant cortical localization (Fig. 5A), and frequently, these transfected cells showed extensive membrane blebbing (Fig. 5A). F-actin stained strongly within the periphery of the blebs but not within the blebs (Fig. 5B). Expression of SPEC2 also showed the same cortical localization, membrane blebbing, and F-actin staining phenotype (Fig. 5, C and D). A similar pattern of cortical staining and blebbing were observed with a myc epitope tag located either at the N or C terminus of SPEC1 and using a 20-fold range of plasmid concentrations (100 ng to 2  $\mu$ g; data not shown). Although this SPEC-induced membrane blebbing is morphologi-





FIG. 4. SPEC1 alters Cdc42 activity in COS1 cells. COS1 cells were transfected with myc-tagged Cdc42-Q61L and processed for indirect immunofluorescence at 24 h post-transfection using monoclonal antibodies specific for the myc epitope tag followed by either Texas Red-conjugated goat anti-mouse antibodies or FITC-conjugated goat anti-mouse antibodies (A, C, and E). Cells transfected with myc-tagged Cdc42-Q61L alone were co-stained for F-actin (B). Cells cotransfected with either FLAG-tagged wild-type SPEC1 (D) or FLAG-tagged SPEC1-H38A (F) were processed for indirect immunofluorescence using a polyclonal FLAG<sup>TM</sup>/octaprobe antibody followed by FITC-labeled goat anti-rabbit secondary antibodies. The morphology of the COS1 cells transfected with Cdc42-Q61L resemble those cotransfected with the SPEC1-H38A mutant (compare A with E). Bar, 10  $\mu$ m.

cally similar to the membrane blebbing associated with apoptosis, there is no functional association of the SPEC-induced blebbing with apoptosis. That is, neither nuclear condensation following 4,6-diamidino-2-phenylindole staining of nuclei nor annexin-V positive staining, a marker for phosphatidylserine flipping in the membrane, was observed in these transfected cells (data not shown).

Quantitatively, membrane blebbing was observed in 40–60% of the FLAG epitope-tagged SPEC1 transfected cells but only in about 5% of cells expressing the vector-alone control (Fig. 6). We also used a bicistronic expression vector expressing both SPEC1 and EGFP from the same vector to rule out the


**FIG. 5. SPEC1 and SPEC2 induce membrane blebbing in NIH-3T3 fibroblasts.** N-terminal FLAG epitope-tagged SPEC1 (A and B) or N-terminal FLAG epitope-tagged SPEC2 (C and D) constructs were transfected into NIH-3T3 fibroblasts. The cells were fixed 24 h after transfection and processed for indirect immunofluorescence using an anti-FLAG monoclonal antibody followed by FITC-conjugated goat anti-mouse secondary antibody to detect SPEC1(A) and SPEC2 (C) protein expression. Cells were co-stained for F-actin using Texas Red conjugated phalloidin (B and D). Bar, 10  $\mu$ m.



possibility that the epitope tags might influence SPEC function. About 40% of the cells expressing the bicistronic SPEC1 construct showed a blebbing phenotype, whereas only 10% were blebbing with the EGFP-alone vector (Fig. 6). Taken together, these results demonstrate that expression of SPECs, whether epitope-tagged or untagged, leads to membrane blebbing in NIH-3T3 fibroblasts.

**SPEC1-induced Blebbing Is Independent of Cdc42 Activity**—To determine whether any of the three conserved regions in SPECs (see Fig. 1) are necessary for SPEC1-induced membrane blebbing, we examined the phenotype of cells transfected with various SPEC1 mutants. An additional N-terminal mutant, SPEC1-C10A,C11A was created within two conserved cysteine residues because of the potential role of these residues in lipid modification or protein interactions. Using cell counting it was found that both the positive and negative controls gave the expected results: approximately 44% of N-terminal FLAG-tagged SPEC1-transfected cells blebbed, as compared with only 4% using a vector-alone control (Fig. 7). The C-terminal double point mutant, SPEC1-Q62A,K66A, had no effect on the level of blebbing (Fig. 7). In contrast, the cells expressing the N-terminal mutant (SPEC1-C10A,C11A), which showed a similar level of expression and cortical localization, produced the blebbing phenotype in only 20% of the transfected cells (Fig. 7). Single or triple amino acid substitutions within the CRIB domain of SPEC1 resulted in somewhat fewer blebs, although they still produced significantly more than the negative controls (30% versus 4%; Fig. 7). Additional studies expressing a dominant negative mutant of Cdc42 (Cdc42-T17N) alone did not induce membrane blebbing, and co-expression with SPEC1 did not block membrane blebbing (data not shown). These results support a model whereby SPEC1-induced blebbing does not occur through classical Cdc42-effector interactions and suggest that SPEC1 may act independently of Cdc42 or perhaps upstream of Cdc42 to induce membrane blebbing. These data also confirm that SPEC-induced membrane changes are not directly due to sequestration of Cdc42.

**SPEC1 Expression Alters Cdc42-induced Changes in Cellular Morphology in NIH-3T3 Fibroblasts**—To more clearly define the relationship between Cdc42 activity and SPECs, we tested the effect of SPEC1/Cdc42 co-expression in NIH-3T3 fibroblasts. In these fibroblasts, expression of Cdc42L61 re-



**FIG. 6. Quantitative analysis of the effect of tagged and untagged SPEC1 on blebbing.** NIH-3T3 fibroblasts were transfected, fixed, and processed for indirect immunofluorescence. NIH-3T3 fibroblasts showing at least two membrane blebs were scored as positive for blebbing as described under "Experimental Procedures"; values indicate mean and S.D. V, pCAF2 vector alone; SPEC1, pCAF2-SPEC1; EGFP, EGFP vector alone; SPEC1-EGFP, bicistronic SPEC1-EGFP vector.

sulted in cells that predominantly exhibited a membrane ruffling phenotype, possibly through activation of Rac signaling. We then cotransfected SPEC1 or the SPEC1-CRIB mutants (SPEC1-H38A or SPEC1-P33A,H38A,H41A) with constitutively active Cdc42 and quantified by cell counting the number of transfected cells showing a ruffling phenotype. Expression of a constitutively active Cdc42 mutant (Cdc42-Q61L), but not wild type Cdc42 (data not shown), in NIH-3T3 fibroblasts induced marked membrane ruffling in 52% of the transfected cells (Fig. 8, A and B). Co-transfection of SPEC1 blocked ruffling in all but 5% of the transfected cells and increased the number of blebbing cells (Fig. 8, C and D). Coexpression of the SPEC-H38A mutant resulted in 34% of the cells showing a membrane ruffling phenotype (Fig. 8, E and F) and resembled cells transfected with Cdc42 alone (compare Fig. 8, A and B, with E and F). Similar results were also obtained with the






FIG. 7. Activity of different SPEC1 mutants in inducing membrane blebbing. Wild-type SPEC1 and different SPEC mutants were transfected into NIH-3T3 fibroblasts. At 24 h post-transfection, cells were fixed, processed for indirect immunofluorescence, and counted for blebbing as described above in the legend to Fig. 6; values indicate the mean and S.D. V, pCAF2 vector alone; SPEC1, pCAF2-SPEC1; C10A, C11A, pCAF2-SPEC1-C10A, C11A; H38A, pCAF2-SPEC1-H38A; Q62A, Q66A, pCAF2-SPEC1-Q62A, Q66A.

SPEC1-P33A, H38A, H41A CRIB mutant (data not shown). It is also worthy to note that in these cotransfections experiments, SPEC1 and Cdc42 proteins appear to localize to similar regions within the cells, suggesting that SPECs and Cdc42 may be contained within the same signaling complexes (Fig. 8). As with COS1 cells, these transfections demonstrate that SPEC1 expression led to an altered Cdc42-induced morphology and that this alteration is dependent on the presence of an intact CRIB domain.

#### DISCUSSION

Here we identify a new family of proteins capable of binding to Cdc42, designated SPECs, found in many eukaryotic species. The two human members, SPEC1 and SPEC2, are the smallest known GTPase-binding proteins. Their small size may explain why they were not detected in previous biochemical screens based on binding to Cdc42. Overexpression of different combinations of SPECs, SPEC mutants, and Cdc42 showed that SPEC expression inhibited Cdc42-induced JNK activity. SPEC overexpression also altered or reversed the cellular morphologies produced when Cdc42 is overexpressed in COS1 cells and in NIH-3T3 fibroblasts. The membrane blebbing induced by SPEC overexpression in NIH-3T3 fibroblasts was not observed in COS1 cells, possibly due to quantitative differences in expression levels of SPEC proteins between the two cell types. Nevertheless, these results show that SPECs are capable of modifying Cdc42-dependent signaling at both the biochemical and cellular levels in a CRIB-dependent manner. SPEC binding could prevent the interaction of Cdc42 with other effector proteins. Consistent with this model, a polypeptide containing just the CRIB domain of PAK can effectively inhibit Cdc42 activation (35), whereas a polypeptide containing the CRIB domain of ACK-1 can act as a Cdc42-specific inhibitor, blocking v-Ha-Ras-induced transformation (36).

However, we do not know if the specific biochemical and biological effects observed here with overexpressed SPECs reflect the normal function of these small proteins. In particular, SPEC overexpression induced membrane blebbing in NIH-3T3 fibroblast that was not blocked by dominant negative Cdc42 expression. Despite these findings, it is still possible that SPECs function in Cdc42-induced morphological changes, since




FIG. 8. SPEC1 alters Cdc42-induced cell shape changes. NIH-3T3 fibroblasts were transfected with myc-tagged Cdc42-Q61L and processed for indirect immunofluorescence at 24 h post-transfection using monoclonal antibodies specific for the myc epitope tag followed by either Texas Red-conjugated goat anti-mouse antibodies or FITC-conjugated goat anti-mouse antibodies (A, C, and E). Cells transfected with myc-tagged Cdc42-Q61L alone were co-stained for F-actin (B). Cells cotransfected with either FLAG-tagged wild type SPEC1 (D) or FLAG-tagged SPEC1-H38A (F) were processed for indirect immunofluorescence using a polyclonal FLAG<sup>TM</sup>/octaprobe antibody followed by FITC-labeled goat anti-rabbit secondary antibodies. The morphology of the NIH-3T3 fibroblasts transfected with Cdc42-Q61L resemble those cotransfected with the SPEC1-CRIB mutant (compare A with E). Bar, 10  $\mu$ m.

a dominant negative approach may not rescue the abnormal morphology of overexpressed SPEC protein. Furthermore, various studies have shown that non-apoptotic membrane blebs function normally in cell spreading (37, 38) and locomotion (39–41). Mechanistically, membrane blebs occur at sites where the cortical actin is locally depolymerized or detached from the membrane (38, 40, 41) via alteration in cortical actin-binding proteins (40), myosin light chain kinase activity (42, 43), and/or focal complex assembly (43). Thus, it is tempting to speculate that SPECs may function as classical Cdc42 effector proteins by altering the normal signaling pathways leading to actin, myosin, and/or focal complex assembly.

The existence of small proteins that bind important signaling molecules is not unique to Cdc42. Recently, an 18-kDa protein, A-kinase anchoring protein-18 (AKAP18), was found to function as a scaffold protein, coupling protein kinase A signaling to calcium and sodium channels (44–46). Interestingly, AKAP18 and SPECs share many structural and functional similarities. First, both are small proteins: AKAP18, SPEC1, and SPEC2 are 81, 79, and 84 amino acids long, respectively. Second, both bind their ligands, protein kinase A or Cdc42, through their central binding regions. Third, both localize to the plasma

membrane. Although the membrane localization of AKAP18 involves lipid modification of the N terminus, we have not yet identified the region required to target SPECs to the membrane in NIH-3T3 fibroblasts. Based on these similarities, we speculate that SPECs, like AKAP18, may function as scaffolding molecules to recruit other signaling proteins to Cdc42 complexes. Future studies are aimed at identifying such SPEC-binding partners.

## REFERENCES

- Kroschewski R, Hall A, and Mellman, I. (1999) *Nat. Cell Biol.* **1**, 8–13
- Drechsel, D. N., Hyman, A. A., Hall, A, and Glotzer, M. (1997) *Curr. Biol.* **7**, 12–23
- Johnson, D. I. (1999) *Microbiol. Mol. Biol. Rev.* **63**, 54–105
- Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995) *Mol. Cell. Biol.* **15**, 1942–1952
- Nobes, C. D., and Hall, A. (1995) *Cell* **81**, 53–62
- Stossel, T. P. (1993) *Science* **260**, 1086–1094
- Burbelo, P., Drechsel, D., and Hall, A. (1995) *J. Biol. Chem.* **270**, 29071–29074
- Hart, M. J., Callow, M. G., Souza, B., and Polakis, P. (1996) *EMBO J.* **15**, 2997–3005
- Kuroda, S., Fukata, M., Kobayashi, K., Nakafuku, M., Nomura, N., Iwamatsu, A., and Kaibuchi, K. (1996) *J. Biol. Chem.* **271**, 23363–23367
- Manser, E., Leung, T., Salihuddin, H., Zhao, Z., and Lim, L. (1994) *Nature* **367**, 40–46
- Martin, G. A., Bollag, G., McCormick, F., and Abo, A. (1995) *EMBO J.* **14**, 1970–1978
- Leung, T., Chen, X., Tan, I., Manser, E., and Lim, L. (1998) *Mol. Cell. Biol.* **18**, 130–140
- Manser, E., Leung, T., Salihuddin, H., Tan, L., and Lim, L. (1993) *Nature* **363**, 364–367
- Teramoto, H., Coso, O. A., Miyata, H., Igishi, T., Miki, T., and Gutkind, J. S. (1996) *J. Biol. Chem.* **271**, 27225–27228
- Symons, M., Derry, J. M., Karlak, B., Jiang, S., Lemahieu, V., McCormick, F., Francke, U., and Abo, A. (1996) *Cell* **84**, 723–734
- Miki, H., Sasaki, T., Takai, Y., and Takenawa, T. (1998) *Nature* **391**, 93–96
- Burbelo, P. D., Snow, D. M., Bahou, W., and Spiegel, S. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 9083–9088
- Joberty, G., Perlungher, R. R., and Macara, I. G. (1999) *Mol. Cell. Biol.* **19**, 6585–6597
- Sells, M. A., Boyd, J. J., and Chernoff, J. (1999) *J. Cell Biol.* **145**, 837–849
- Bagrodia, S., Derijard, B., Davis, R. J., and Cerione, R. A. (1995) *J. Biol. Chem.* **270**, 27995–27998
- Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., and Bokoch, G. M. (1995) *J. Biol. Chem.* **270**, 23934–23936
- Brown, J. L., Stowers, L., Baer, M., Trejo, J., Coughlin, S., and Chant, J. (1996) *Curr. Biol.* **6**, 598–605
- Rudel, T., and Bokoch, G. M. (1997) *Science* **276**, 1571–1574
- Yang, W., Lin, Q., Guan, J. L., and Cerione, R. A. (1999) *J. Biol. Chem.* **274**, 8524–8530
- Tibbles, L. A., Ing, Y. L., Keifer, F., Chan, J., Iscove, N., Woodgett, J. R., and Lassam, N. J. (1996) *EMBO J.* **15**, 7026–7035
- Nagata, K., Puls, A., Futter, C., Aspenstrom, P., Schaefer, E., Nakata, T., Hirokawa, N., and Hall, A. (1998) *EMBO J.* **17**, 149–158
- Suetsugu, S., Miki, H., and Takenawa, T. (1998) *EMBO J.* **17**, 6516–6526
- Machesky, L. M., and Insall, R. H. (1998) *Curr. Biol.* **8**, 1347–1356
- Rohatgi, R., Ma, L., Miki, H., Lopez, M., Kirchhausen, T., Takenawa, T., and Kirschner, M. W. (1999) *Cell* **97**, 221–231
- Aspenstrom, P., Lindberg, U., and Hall, A. (1996) *Curr. Biol.* **6**, 70–75
- Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) *Cell* **81**, 1137–1146
- Abdul-Manan, N., Aghazadeh, B., Liu, G. A., Majumdar, A., Ouerfelli, O., Siminovich, K. A., and Rosen, M. K. (1999) *Nature* **399**, 379–383
- Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., Manser, E., Lim, L., and Laue, E. D. (1999) *Nature* **399**, 384–388
- Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) *Cell* **81**, 1147–1157
- Osada, S., Izawa, M., Koyama, T., Hirai, S., and Ohno, S. (1997) *FEBS Lett.* **404**, 227–233
- Nur-E-Kamal, M., Kamal, J., Qureshi, M., and Maruta, H. (1999) *Oncogene* **18**, 7787–7793
- Erickson, C. A., and Trinkaus, J. P. (1976) *Exp. Cell Res.* **99**, 375–384
- Cunnigham, C. C. (1995) *J. Cell Biol.* **129**, 1589–1599
- Trinkaus, J. P. (1980) *Prog. Clin. Biol. Res.* **41**, 887–906
- Keller, H., and Eggle, P. (1998) *Cell Motil. Cytoskeleton* **41**, 181–193
- Cunningham, C. C., Gorlin, J. B., Kwiatkowski, D. J., Hartwig, J. H., Janmey, P. A., Byers, H. R., and Stossel, T. P. (1992) *Science* **255**, 325–327
- Mills, J. C., Stone, N. L., Erhardt, J., and Pittman, R. N. (1998) *J. Cell Biol.* **140**, 627–636
- Huot, J., Houle, F., Rousseau, S., Deschesnes, R. G., Shah, G. M., and Landry, J. (1998) *J. Cell Biol.* **143**, 1361–1373
- Fraser, I. D., Tavalin, S. J., Lester, L. B., Langeberg, L. K., Westphal, A. M., Dean, R. A., Marrion, N. V., and Scott, J. D. (1998) *EMBO J.* **17**, 2261–2272
- Gray, P. C., Tibbs, V. C., Catterall, W. A., Murphy, B. J. (1997) *J. Biol. Chem.* **272**, 6297–6302
- Tibbs, V. C., Gray, P. C., Catterall, W. A., and Murphy, B. J. (1998) *J. Biol. Chem.* **273**, 25783–25788

# The genomic structure of the human SPEC1 gene reveals complex splicing and close promoter proximity to the AF1q translocation gene

Dana M. Pirone, Michael D. Oberst, Dora Stylianou, Peter D. Burbelo\*

*Lombardi Cancer Center and the Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA*

Received 12 February 2001; received in revised form 3 May 2001; accepted 6 June 2001

Received by J.L. Slightom

## Abstract

SPECs are small Cdc42 signaling molecules. In mammals, two genes, SPEC1 and SPEC2, encode proteins of 79 and 84 amino acid residues, respectively. Here we report the expression and genomic organization of the human SPEC1 gene. Using Northern blot analysis, three major SPEC1 mRNA transcripts of 1.6, 3.3, and 6.3 kb were detected. Identification and sequencing of different sized SPEC1 cDNA clones revealed that the transcript size heterogeneity was due to alternative splicing in the 3'-untranslated region. In addition, a distinct SPEC1 splice variant from within the coding sequence, SPEC1- $\beta$ , was identified and detected in a variety of human tissues. Analysis of the genomic organization of SPEC1 revealed that the coding sequence of the SPEC1 isoform was derived from exons 2, 3 and 4, while the SPEC1- $\beta$  isoform was derived from exon 2 and a read-through event of intron 2. Examination of the 5'-end of the SPEC1 genomic sequence revealed that AF1q, a previously identified gene involved in translocations with the MLL (mixed-lineage leukemia) gene, was 631 bp away in a head-to-head orientation. This intergenic sequence containing the putative promoter region for both SPEC1 and AF1q genes did not contain a TATA box or CAAT box. Transfection experiments using an AF1q promoter luciferase reporter construct in a variety of cells including Cos1 cells, Jurkat T-cells, MCF-7 breast cancer cells, and NIH-3T3 fibroblasts showed no promoter activity. In contrast, a SPEC1 promoter luciferase reporter construct showed high levels of reporter activity in Cos1 and MCF-7 cells, low activity in NIH-3T3 fibroblasts and no activity in Jurkat T-cells. These promoter analyses suggest that although SPEC1 and AF1q genes share the same promoter region, they are not coordinately regulated. © 2001 Elsevier Science B.V. All rights reserved.

**Keywords:** Alternative splicing; Cdc42; Gene expression; Promoter region; Translocation

## 1. Introduction

The Cdc42 GTPase is a signaling molecule that regulates a diverse array of biological processes (Johnson, 1999). Most prominently, Cdc42 regulates actin polymerization leading to the formation of filopodia and other actin-containing structures (Kozma et al., 1995; Nobes and Hall, 1995). In addition to these cytoskeletal effects, Cdc42 can also regulate other biological processes such as cytokinesis (Dutartre et al., 1996; Drechsel et al., 1997), cell

polarity (Kroschewski et al., 1999) and a variety of kinase signaling pathways leading to transcriptional activation (for review, see Johnson, 1999). A large and diverse set of molecules has been identified that interact with Cdc42 and function as downstream effector proteins. A common feature of many of these Cdc42 effector proteins is the presence of a CRIB/GBD domain involved in binding Cdc42 (Burbelo et al., 1995; Pirone et al., 2001). To date, nine distinct families of human CRIB domain-containing Cdc42 effector proteins derived from 25 genes have been identified: ACK (Manser et al., 1993), PAK (Manser et al., 1994), MLK (Burbelo et al., 1995; Teramoto et al., 1996), WASP (Symons et al., 1996; Miki et al., 1998), MRCK (Leung et al., 1998), MSE55/CEP/BORG (Burbelo et al., 1999; Joberty et al., 1999; Hirsch et al., 2001), Gene 33 (Makkinje et al., 2000), PAR-6 (Qiu et al., 2000) and SPECs (Pirone et al., 2000).

Of all the CRIB-containing Cdc42-binding proteins, the SPEC family members are the smallest in size (Pirone et al., 2000). In humans, two distinct genes, SPEC1 and SPEC2,

Abbreviations: CRIB, Cdc42/Rac interactive binding domain; EST, expressed sequence tag; MLL, mixed-lineage leukemia; RT-PCR, reverse transcription-polymerase chain reaction; SPEC, small protein effector of Cdc42

\* Corresponding author. Room E320, New Research Building, Lombardi Cancer Center, 3970 Reservoir Road, N.W., Georgetown University Medical Center, Washington, DC 20007, USA. Tel.: +1-202-687-1444; fax: +1-202-687-7505.

E-mail address: burbelpd@gunet.georgetown.edu (P.D. Burbelo).



encode proteins of 79 and 84 amino acid residues, respectively. Analysis of SPEC homologs from a number of additional species including *Drosophila*, chickens, and mice reveal that they are highly conserved and contain a central CRIB domain involved in Cdc42 binding. Transfection analysis showed that SPEC1 blocks Cdc42-induced JNK activity and Cdc42-induced morphological activities, suggesting a potential role in blocking Cdc42 activity. Although the exact biological function of these molecules is still not completely known, overexpression of SPEC1 and SPEC2 in NIH-3T3 fibroblasts induces the formation of cell surface membrane blebs, suggesting that they may normally function in focal complex assembly or cortical membrane integrity (Pirone et al., 2000).

In view of the biological activities and unusually small size of SPEC1, we have characterized its RNA distribution, genomic organization and promoter activity. We have determined that SPEC1 mRNA is ubiquitously expressed and has several different mRNA transcripts that arise through alternative splicing in the 3'-untranslated region. We have also identified a SPEC1 splice variant from within the coding sequence, SPEC1- $\beta$ , and demonstrate using RT-PCR that it is ubiquitously expressed. Sequence comparison of the SPEC1 cDNA with a SPEC1-containing BAC genomic clone revealed that the gene was composed of six exons of which exons 2, 3, and 4 generate the coding sequence. By analyzing the 5'-end of the SPEC1 gene, we found that the AFIq gene is in a head-to-head orientation with the SPEC1 gene and is separated by a maximum distance of approximately 600 bp. Functional promoter analysis of this intergenic sequence revealed transcriptional activity for the SPEC1 gene, but not for the AFIq gene, suggesting that additional regulatory elements are required for AFIq transcriptional activity.

## 2. Materials and methods

### 2.1. Northern blot analysis

Two multiple tissue Northern blots (Life Technologies, Rockville, MD) containing immobilized polyA<sup>+</sup> mRNA (2  $\mu$ g each) from several human tissues were probed for SPEC1 mRNA expression. Two different probes were generated, both of which were derived from the 1.2 kb SPEC1 cDNA (Pirone et al., 2000). One of the probes was derived from the 3'-end of the SPEC1 cDNA (nucleotides 574–1286), while the second probe was derived from the 5'-end of the SPEC1 cDNA (nucleotides 1–312). In each case the corresponding plasmid templates were first linearized and then used in an RNA polymerase transcription reaction with T3 RNA polymerase and [<sup>32</sup>P]UTP (3000 Ci/mmol). The resulting high specific activity antisense riboprobes were each hybridized at 65°C under stringent conditions. Following hybridization, the blots were washed and exposed to X-ray film for 72 h.

### 2.2. Identification and characterization of SPEC1 splice forms

Several cDNA clones overlapping the 3'-end of the original 1.2 kb SPEC1 sequence (Pirone et al., 2000) were identified from a BLASTN search of the EST database. One of the clones (I.M.A.G.E. Consortium clone ID: 1627665) was obtained and sequenced on an Applied Biosystem 377 DNA sequencer by primer walking. The GenBank Accession number for the sequence of this 3.2 kb contig is AF18784.

In addition to these 3'-end overlapping clones, two cDNA clones encoding a distinct isoform, SPEC1- $\beta$ , were also identified. These cDNA clones were obtained from the I.M.A.G.E. Consortium (clone IDs: 713828 and 207095) and sequenced. The sequence of one of the SPEC1- $\beta$  clones (clone ID: 207095), containing a 2.2 kb cDNA insert, is available from GenBank under Accession number AF286592.

### 2.3. RT-PCR

RT-PCR analysis was used to determine whether SPEC1 and SPEC1- $\beta$  isoforms were present in human tissues. The primers for SPEC1 amplification are: 5'-ATTTTGGCA-CAAAGTGGGCT-3' and 5'-CTATAAGCCCCCTAGAA-TTGC-3' (see Fig. 4). The primers for amplifying the SPEC1- $\beta$  cDNA are: 5'-TGAGTCTCCCCACCCCCCAT-3' and 5'-GCTCCATGGCCTATCTCGGT-3' (see Fig. 4). To distinguish between the SPEC1- $\beta$  mRNA and genomic contamination, SPEC1- $\beta$  primers were designed to span intron 3 from intron 2 of SPEC1- $\beta$  to exon 4 (see Fig. 4). The PCR reactions utilized a panel of cDNAs from different human tissues as template (OriGene Technologies, Inc., Rockville, MD). Thirty-five cycles of PCR were run according to the following step program: 45 s of denaturation at 95°C, 45 s of annealing at 47°C, and 1 min of extension at 72°C. As positive controls for SPEC1 and SPEC1- $\beta$  amplification, plasmids containing the corresponding cDNAs were used as template. For each set of reactions a water control was also employed. The PCR products were separated on a 1% agarose gel and stained with ethidium bromide. Southern blot analysis was also performed with a SPEC1-specific cDNA probe to confirm the specificity of the observed PCR products.

### 2.4. In vitro transcription and translation

Coding sequences for SPEC1 and SPEC1- $\beta$  were cloned downstream of the T7 promoter in the pcDNA3 vector (Invitrogen, Carlsbad, CA). *In vitro* transcription and translation was performed using the coupled TNT<sup>®</sup> system (Promega, Madison, WI). In place of [<sup>35</sup>S]methionine labeling, a colorimetric, non-isotopic method using biotinylated lysine charged t-RNAs was utilized (Promega). In each reaction, 2  $\mu$ g each of pcDNA3, pcDNA3-SPEC1, or pcDNA3-SPEC1- $\beta$  was used in a 50  $\mu$ l reaction mixture containing 40  $\mu$ l of rabbit reticulocyte lysate, 1  $\mu$ l of

methionine, and 2  $\mu$ l Transcend™ Biotin-Lysyl-tRNA. Each reaction mixture was incubated for 1 h at 30°C and biotinylated proteins were affinity-purified using Soft-Avidin-agarose as described by the manufacturer (Promega). The biotinylated proteins were then resolved on an 18% SDS-PAGE gel, transferred to nitrocellulose, and detected colorimetrically using a streptavidin-alkaline phosphatase (Promega).

### 2.5. Isolation and characterization of a genomic clone for the *SPEC1* gene

A 0.6 kb fragment of the *SPEC1* cDNA was amplified by PCR using primers specific to the *SPEC1* gene sequence (forward primer, 5'-TGAGTCTCCCCACCCCAT-3' and reverse primer, 5'-AGTCAGCACGGAGGAAGGA-3') and Vent polymerase (New England Biolabs Inc., Beverly, MA). This PCR product was gel-purified, radiolabeled, and used as a probe to screen a human BAC library (Research Genetics, Huntsville, AL) under stringent conditions. One positive clone was obtained from this screen. Using PCR analysis and DNA sequencing, this BAC clone was found to correspond to the human *SPEC1* gene. Using this sequence information, the exon and intron splice junctions were determined.

### 2.6. Transfection and reporter assays

A 776 bp region containing the 5'-untranslated sequences of both the *AF1q* and *SPEC1* genes and the corresponding intergenic region was amplified from the BAC clone containing *SPEC1* using primers 5'-CCAGACGTTTCAGC-TACAGCT-3' and 5'-TATTCCTCGATCTCTTCCAGC-3'. This sequence is available from GenBank under Accession number AY026491. The PCR product was subcloned in both orientations into the luciferase reporter vector, pXP (Nordeen, 1988). The construct corresponding to orientation for the promoter for the *SPEC1* gene was designated pXP-SP while that for the *AF1q* gene was designated pXP-AF. For functional promoter analysis, 1  $\mu$ g of either the pXP control vector or pXP promoter constructs were co-transfected along with 5 pg of the plasmid for CMV-*Renilla* luciferase. Jurkat T-cells were maintained in RPMI medium supplemented with 10% fetal bovine serum (FBS) and were transfected by electroporation (250 V, 960  $\mu$ F). Cos1 cells were grown in DMEM supplemented with 10% FBS, while MCF-7 breast cancer cells were grown in IMEM supplemented with 10% FBS. Both Cos1 and MCF-7 cells were transfected using Fugene reagent (Roche, Indianapolis, IN) according to the manufacturer's instructions. NIH-3T3 fibroblasts were maintained in DMEM supplemented with 10% calf serum and were transfected using Lipofectamine Plus transfection reagent (Life Technologies, Rockville, MD). Luciferase assays were performed using the Dual-Luciferase™ Reporter Assay System (Promega) and measured on a LB9501 Berthold luminometer. Transfec-

tions were performed in triplicate and promoter activity is representative of three different experiments.

## 3. Results

### 3.1. Northern analysis reveals multiple *SPEC1* mRNA transcripts

Using Northern blot analysis with a probe derived from the 3'-untranslated region of the 1.2 kb *SPEC1* cDNA (Pirone et al., 2000), we detected the ubiquitous expression of three major transcripts of 1.6, 3.3, and 6.3 kb in brain, uterus, placenta, kidney, spleen and lung (Fig. 1A). In these tissues a minor transcript of 10.2 kb was also detected (Fig. 1A). To rule out non-specific hybridization, a second probe directed against the 5'-untranslated region of *SPEC1* was used in a matched blot. Hybridization with this alternate probe showed an identical distribution pattern to that seen with the 3'-untranslated probe (Fig. 1B). Northern analysis using a probe derived from the coding region of *SPEC1* also detected the same pattern of mRNA transcripts (data not shown). These Northern data suggest that the different sized *SPEC1* mRNA transcripts are derived from alternative splicing. Furthermore, the Northern results seen with the three independent probes demonstrate that the 1.6, 3.3, and 6.3 kb mRNA transcripts all share the originally determined 1.2 kb *SPEC1* cDNA sequence.

### 3.2. Identification of additional *SPEC1* cDNAs containing an alternative 3'-end

In an effort to identify the larger *SPEC1* mRNA species, we searched the EST database for cDNA clones that over-




Fig. 1. Northern analysis of *SPEC1* mRNA. (A) A blot containing polyA<sup>+</sup> RNA from a variety of human tissues was analyzed for *SPEC1* expression using a probe derived from the 3'-untranslated region of *SPEC1* (nucleotides 574–1286). Three major transcripts of 1.6, 3.3, and 6.3 kb were detected as well as a minor transcript of 10.2 kb. (B) Using a 312 bp probe derived from the 5'-untranslated region of *SPEC1* (nucleotides 1–312) on a paired blot revealed a similar pattern and expression levels as that seen in (A). The molecular weight markers are indicated in kb.

lapped the previously determined 1.2 kb cDNA sequence of SPEC1. Identification and sequencing of several new overlapping SPEC1 cDNA clones revealed an additional 1.8 kb of 3'-untranslated sequence that contained no additional open reading frames. Sequence analysis of several different SPEC1 cDNA clones revealed that they utilized one of two different polyadenylation signals, one located at nucleotides 1282–1286 and the other at nucleotides 2987–2991 (Fig. 2). These results support the data from the SPEC1 Northern analysis and confirm that the 1.6 and 3.3 kb SPEC1 mRNA species are due to alternate usage of these polyadenylation sites.

### 3.3. SPEC1 and SPEC1- $\beta$ isoforms are present in multiple human tissues

In addition to the 3'-end alternatively spliced SPEC1 clones, we also identified and sequenced an additional isoform that had an altered protein coding sequence distinct from that of SPEC1. This isoform, SPEC1- $\beta$ , was initially detected as two different clones from EST database searches. The SPEC1- $\beta$  translation product would encode a 38 amino acid protein, in which the first 18 amino acids

would be identical to SPEC1 (Fig. 3A). SPEC1- $\beta$  would also contain a unique proline rich C-terminus, ending in a CAAX box-like sequence (Fig. 3A). Specifically, the C-terminal, C-A-V-R sequence of SPEC1- $\beta$  may be involved in plasma membrane targeting as it is in other proteins such as Ras (Hancock et al., 1991; Moores et al., 1991).

To examine the distribution of the SPEC1- $\beta$  mRNA isoform, we performed RT-PCR with human cDNAs derived from lung, placenta, heart, kidney, liver, and colon. In these experiments, we used two different sets of primers to amplify either the SPEC1 or SPEC1- $\beta$  cDNAs. Using RT-PCR, we obtained the expected 230 bp fragment corresponding to SPEC1 in all tissues examined (Fig. 3B). In the case of SPEC1- $\beta$  detection, we designed primers spanning intron 3 to differentiate between SPEC1- $\beta$  cDNA and potential genomic contamination (see Section 2). Using these SPEC1- $\beta$ -specific primers, a 720 bp fragment corresponding to the SPEC1- $\beta$  cDNA was amplified in all of the same tissues (Fig. 3B). In each case, SPEC1 and SPEC1- $\beta$  products were confirmed using Southern blotting (data not shown). Based on experiments using primers common to both SPEC1 and SPEC1- $\beta$ , we consistently observed a much lower level of SPEC1- $\beta$  expression as

1	CAGAGCTAGCCCGGGAAGCCACACTGGCGGCCACGGAGCAGAGTCCCTCACCCCCACAGCTGTAGCTGAACGCTCTGGATGGTGGAGAA	
91	GAGCAGGGTTCGAGTCTGAGGAAGACATAACCTTGTGCCTGCCTGCCACCTCTCTCTGGTCTGTTCATCTCTCAGGCTCTGAGAC	
181	ACTGACCTTCACTGCTCAGTTAAAGGTTCCAGGGATTCCACTTTGTCTGGACCCATCCAGCTGAGTGAACCCAGGGTGGTGGTATCTG	
271	GGGAGAGTGAGGAGTGGGTTGTCCAAACACAGGGAAGAGCCCTTTGGGGCTCAGACAGAGGAGTGAAGCTGGAACCATCAGGGAACA	
		M 1
361	TGAGTGAATTTTGGCACAAACTGGGCTGCTGTGTGGTAGAGAAACCCAGCCGAGAAGAAGAGAAGACGGATTGACCGGACCATGATTG	
	S E F W H K L G C C V V E K P Q P K K K R R R I D R T M I G	31
451	GGGAACCAATGAATTTTGTTCACCTGACTCACATTGGCTCAGGGGAGATGGGGCCGGAGATGGACTGGCATGACAGTGGCAVTCAGG	
	E P M N F V H L T H I G S G E M G A G D G L A M T G A V T Q E	61
541	AGCAGATGAGATCCCAAGGGAACCCGATAGGCCATGGAGCAATTCAGGGGCTTATAGCTCCAATAATGAATGGTTCTGCCATCTTGA	
	Q M R S K G N R D R P W S N S R G L *	79
631	AACCCCATCTGTTTCCAGCCAGGAAGATGCTGCCCTTACCAGATCCCTCCTTGAACCAAGTATCTAAGGACCCCTCTTTTCCCTAT	
721	CTGCCATAACAGTGCCTCACAAGGCTTGGGGCTGGACTCCCTCTACTCCCTCTGGCCATAGCCCTCTCTGGAGATGGGGTCAAGGCAGCA	
811	GGACTGATCAAGTACTACTGTTAGCCAGAGGGAGCGCTGAAGCCTAGGAAACCCCTCAGGTCTGAGATAGGAGTCTCTAGGAACCTGG	
901	AATGAGTCTCTGCTCCTGAATGATGCTGGGTGCCACCTGTTTTAACTCTTAAACCTGGAACCTCTTAAATGGGGTAGGTGGGTGA	
991	GATTATCAAGCTGAAGCTGGCTTGGCTGAGAAGCTCCCTACCTGCCCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	
1081	GTCTAAGCAGGGGCTGGGGGGTGGCTACTCCCTTTTCCACTCTATCTTTAGATTTCAAACCTTAGGCTTACAGCCCTCAATATCTCTCT	
1171	GCTAACACCAAGTGTCTCTTCTAGTTAGGCCCTCTAATCTTCTGTCTGTCTTACAGCTTCCAGCAACTTCTCTTTTAAATATTTAA	
1261	AAATTTAATTCAGGTTCTCTTAATATCTCTCATCTGCTGTTCTCTCGCCCTTAACCTATCCCTATTAGGAACCTGTTTCCACCGAA	
1351	TAAGAGTTAAGGTTAAGAGTAGCTCTTCACCTGATGACATTCATTAAAGTTTGGGGCATCTTCTCTGCCCTCTGCCAACCTCCCTGCT	
1441	GGCCCAAGTGAGAGGAGGAAGAGGGGCTGGAAAGAAACCCAGAATCGGCAGAACTAGGAGTAAGTCCATCTCAAGGTGGACTTCTGAT	
1531	CATTGAGGATGGTGAGATAAATAGGTTGAAACCAATCATCTGTGAGTTTAGGAGTCTTAAGATCCTCACAGCACGGGAGCAGGGAGAGGC	
1621	TCTAGAACAAGGTTTCAACAACCGAGATGCTTTGACATTTTGGGCTGAAGTGTCTTTTGAAGGAAACCTGTTTCTTATTTTGTGCATT	
1711	ACAGGATATTTAGCAGCAGCGCTGGCCCACTCTAGTTATGACAACCAAAATGTCTCTATACATTGCCAGATTTCTCTTAGGGGGCAAAA	
1801	TCGCCTCCATTGAGACTCAACTCTGAGTTCCGTAGGGGGCAAAATCGCCTCCATTTGAGAACCACAACCTCTAAAGTCAAGATATTTT	
1891	CTCTGAAGTGATTTCTGCTTGGCAGCTACCTCATCTTACTCATCTTAAGCCGAGCATGGATCAACTAGGAGCCCATATAAATGA	
1981	GGCTCAGTAGGGCTGACATAATCTCCAAACAATCTTTAATTCAGTGTATTGCTTGGTGTTCATGTTGCTATGATTGGAACAAGGTTT	
2071	CCCCTCTCCATTCTTGCCTCTGGAGAAGTGGTCTCTGCAGTGTAGAGATATGAACAGGGTATGGTAGGATTGGGGAAGGGGAGAGAG	
2161	AAGCAGTAGATACACTCTTATCTCTCCCAATTTTAAGCTCTATTTTGTGCCCTAGTCTCTAGACACATTAGACTCAGGGAGTTTTG	
2251	TCTGAAGACCACTCCCACTGCCCTGGCTGAAGAGTCTGCTTTAATGGGAAACCAACGTAGGAGCAGGGGTTTTTAGGCACCTTTCAG	
2341	TTTTCTCAGGTGTTCTTCTGTTTGGCCCTTCCAGGGTAATTAGGAAGGCAGAACAGACAGATGAGTCTCTGCTCTGAGACAAGAA	
2431	GGGTGGGGTCTCATAGCTTTGCAACAGGAACATCTCTGTTTATTTAGTGTAGTGGGGTCAGGAATGAGGAACCTGGTATCCATTCTGCC	
2521	AATTCACCAACCATTCAGTTTGTCTTATCCCTACAGAACAGTGAAGTGTCTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCT	
2611	GTTATTTCTGCAATTTTTCAGGGTCTAAGATTGGTCATACATTTCCCAATTTACTCTCAGTTCAGTCAAGCTGGTGTGCTCTGAAAGTAAC	
2701	CCAGCTTGTGCTCTAAATACCTCAGTAGCTGAGTGTATCTAGAGATCTAAGGGTTAAGAGGATAGGGTGAAGAGGTTAGAGACT	
2791	CCTAGAAATCTCTGGTACCGTGATCTTGGCCCTCATTCTAATACCTGTTCTTTGGACAGTCTTTTCTTTTGGTGTCTCTTGCCTTTA	
2881	GCTACCTTCTCTAATATGATGCTACCATCAATAAAGTGATGGGAATGGGTTTGAAGTGTGTAATTTATATTAATAAAGGTTGTTGGAC	
2971	TTTTAATACATTTTTCATAAATAAATAAAGTAAAGCAAAAT	

Fig. 2. Nucleotide and amino acid sequences of the human SPEC1 cDNA. Nucleotides are numbered on the left; amino acid residues are numbered on the right. The sequence shown is a composite of several overlapping clones. Analysis of various cDNA clones revealed that they encoded two different mRNA species, which arose from different 3'-polyadenylation signals. The two different polyadenylation signals are underlined.




Fig. 3. Identification and expression of SPEC1- $\beta$ . (A) Amino acid alignment of SPEC1 and SPEC1- $\beta$  proteins. The numbers indicate the size of the proteins in amino acid residues. The N-terminal 18 amino acids which are common to SPEC1 and SPEC1- $\beta$  are underlined. The potential CAAX motif of SPEC1- $\beta$  is in bold font and underlined. (B) Expression analysis of SPEC1 and SPEC1- $\beta$  mRNA by RT-PCR in a variety of human tissues. PCR-amplified products were resolved on a 1% agarose gel and stained with ethidium bromide. The + denotes the appropriate positive controls generated from SPEC1 and SPEC1- $\beta$  plasmid clones. The sizes of the PCR products are indicated to the left of the gel. (C) *In vitro* transcription and translation of SPEC1 and SPEC1- $\beta$  cDNAs. The coding regions of both SPEC1 and SPEC1- $\beta$  were cloned into the pcDNA3 vector and used for *in vitro* transcription and translation. In these reactions biotinylated lysine residues were incorporated into the protein products. Translated products were separated on an 18% SDS-PAGE gel, transferred to nitrocellulose, probed with streptavidin-alkaline phosphatase conjugate and detected colorimetrically. The molecular weights are indicated to the left of the blot. The arrows to the right of the blot indicate the positions of the SPEC1 and SPEC1- $\beta$  protein products.

compared to SPEC1 (data not shown). These results confirm the presence of SPEC1- $\beta$ , but suggest that it is present only as a minor transcript.

Because of the unusually small size of the SPEC1- $\beta$  mRNA isoform, we used *in vitro* transcription and translation to examine whether the SPEC1- $\beta$  cDNA could generate a protein product. In these experiments, plasmid constructs were generated containing SPEC1 or SPEC1- $\beta$  cDNAs downstream of the T7 promoter. In this *in vitro* transcription and translation system, the incorporation of biotinylated lysine residues was used to monitor protein production. Analysis of the translation products on an 18% SDS-PAGE gel revealed that SPEC1 and SPEC1- $\beta$  generated 8 and 4 kDa protein species, respectively (Fig. 3C). In contrast, no protein product was observed with the sample containing no DNA or with the empty vector control (Fig. 3C). These results support the possibility that the SPEC- $\beta$  protein is translated *in vivo*.

### 3.4. Characterization of the SPEC1 exon–intron structure

To further understand the organization of the SPEC1 gene and the origin of the mRNA splice variants, a single BAC clone was isolated from a genomic library with a SPEC1-specific probe. While this work was in progress, the working draft sequences of a bacterial artificial chromosome clone (RP11-316M1) containing the SPEC1 gene became available through the Human Genome Project and we have used these data in conjunction with our sequence data to determine the exon–intron organization of the SPEC1 gene. Characterization of the SPEC1 BAC clone by DNA sequencing and PCR analysis revealed that both the entire 1.6 and 3.3 kb SPEC1 cDNAs were encoded by six exons (Fig. 4). Of these six exons, only exons 2, 3 and 4 encoded the 79 amino acid residues of the SPEC1 protein. Exon 2, consisting of 320 bp, contained the start methionine and the first 18 amino acids of the SPEC1 coding sequence (Fig. 4). Exon 3

was 111 bp and encoded the entire CRIB domain responsible for Cdc42 binding, while exon 4 encoded the C-terminal 24 amino acids of SPEC1 and was 93 bp long (Fig. 4). The difference in the 3'-ends of the 1.6 and 3.3 kb species was due to alternative splicing in exon 6, whereby an additional 1.8 kb of 3'-untranslated sequence generates the 3.3 kb cDNA. We also compared the SPEC1- $\beta$  cDNA sequence with the genomic sequence of SPEC1 to formally prove that the SPEC1- $\beta$  cDNA was derived from the SPEC1 gene. Comparison of these sequences revealed that the 0.5 kb intron located between coding exons 2 and 3 was retained in the SPEC1- $\beta$  cDNA, although other introns in the SPEC1 gene were properly spliced (Fig. 4). Finally, using fluorescent *in situ* hybridization the SPEC1 gene was localized to human chromosome 1q21.1-1q21.3, consistent with the sequence and mapping data of the Human Genome Project (data not shown).

### 3.5. SPEC1 and AF1q genes are in a head-to-head arrangement

In the process of characterizing the genomic sequence flanking exon 1 of SPEC1, we identified that the AF1q gene is in close proximity to the 5'-end of the SPEC1 gene. AF1q encodes a small protein of 90 amino acids of unknown function that was previously discovered as a translocation partner with the MLL gene in patients with acute myelomonocytic leukemia (Tse et al., 1995; Busson-Le Coniat et al., 1999; So et al., 2000). The AF1q message of 1.8 kb is restricted to hematopoietic cells, unlike SPEC1 (Tse et al., 1995). Alignment of the genomic sequences of these two genes revealed that SPEC1 and AF1q are in a head-to-head orientation separated by a distance of 631 bp

(Fig. 5). Further sequence analysis of this intergenic region revealed that this sequence did not contain a TATA or CAAT box. However, putative binding sites for several transcription factors were identified, including a GC box as well as putative CdxA, GATA-3, and CP2 binding sites (Fig. 5).

### 3.6. The intergenic region between SPEC1 and AF1q genes has SPEC1 promoter activity

To test whether this region was transcriptionally active for both genes, a 776 bp segment containing the putative promoter region as well as some 5'-untranslated sequence from both SPEC1 and AF1q genes was subcloned in both directions into a promoterless luciferase reporter construct, pXP. The construct corresponding to the promoter for SPEC1 was designated pXP-SP while that of AF1q was designated pXP-AF. Transfection analysis of the SPEC1 promoter construct revealed that it was highly active in Cos1 and MCF-7 cells, weakly active in NIH-3T3 fibroblasts and inactive in Jurkat T-cells. Furthermore, a relatively similar level of activity of the CMV-*Renilla* luciferase construct was observed in each cell type. The AF1q promoter construct showed only background levels of luciferase activity similar to the pXP vector control construct in all cell lines tested (Fig. 6). Interestingly, the SPEC1 promoter appears to have some level of tissue-specific regulation. In particular, the SPEC1 promoter was highly active in Cos1 cells and MCF-7 breast cancer cells, but was less active in NIH-3T3 fibroblasts and inactive in Jurkat T-cells (Fig. 6). These results suggest the possibility that the SPEC1 promoter exhibits epithelial tissue specificity. Using Northern analysis, we have confirmed high




Fig. 4. Genomic structure of the SPEC1 gene. The boxes represent the six exons of the SPEC1 gene, while intron sequences are indicated by a thin line. The site of the 3'-end alternative splicing in exon 6 is indicated by a bar labeled for the 3'-splice site (3'-SS). Lengths of exons and introns are indicated in bp. In addition to the genomic organization corresponding to the SPEC1 cDNA, the origin of the SPEC1- $\beta$  mRNA product is also shown involving the retention of intron 2 as denoted by the hatched box. Met indicates the start of translation and the asterisk (\*) indicates the stop codon. The arrows below the schematics of SPEC1 and SPEC1- $\beta$  mRNAs correspond to the primers used for RT-PCR.






Fig. 5. DNA sequence of the intergenic region between the SPEC1 and AF1q genes. The nucleotide sequence is numbered to the right. The capital letters indicate the 5'-untranslated region of the SPEC1 and AF1q genes while the small letters represent the intergenic sequence located between both genes. The intergenic region begins at nucleotide 41 and ends at nucleotide 671. The arrows indicate the direction of transcription for each gene. The putative binding sites for several transcription factors are underlined.

levels of SPEC1 mRNA expression in a variety of breast cancer cells (data not shown).




Fig. 6. SPEC1 promoter activity. Promoter constructs for both SPEC1 and AF1q were constructed in the promoterless luciferase reporter vector pXP. The control vector (pXP), the promoter for SPEC1 (pXP-SP), or the promoter for AF1q (pXP-AF) were co-transfected into Cos1, NIH-3T3, Jurkat T, and MCF-7 cells with a construct for CMV-*Renilla* luciferase. Luciferase assays were performed 24 h post-transfection. Promoter activity is reported as normalized relative light units (RLU) as compared to *Renilla* luciferase activity to normalize for transfection efficiency. Luciferase assays were performed in triplicate and are representative of three different experiments. Error bars indicate standard deviation.

#### 4. Discussion

The SPEC family of proteins, consisting of SPEC1 and SPEC2, represents the smallest known Cdc42-binding proteins (Pirone et al., 2000). Here we have delineated the genomic structure of the SPEC1 gene, and have determined that it contains six exons spanning over 10 kb. Of these exons, only exons 2, 3, and 4 encode the 79 amino acids of the SPEC1 protein. Interestingly, the structure of the human SPEC1 gene is very similar to that of the human SPEC2 gene located at 5q31 (Pirone et al., 2000), whereby three similar sized coding exons encode the full-length proteins. One marked difference in the genomic structure between SPEC1 and SPEC2 is the presence of a 26 kb intron between coding exons 1 and 2 of SPEC2 (Pirone et al., 2000), while only a 551 bp intron region is found between the corresponding exons of SPEC1. Based on these similarities in the genomic structure of the coding regions of the SPEC genes, it is likely that both SPEC genes evolved from one another.

In the course of these studies, we have identified heterogeneity in the 3'-untranslated sequences of the SPEC1 mRNA producing transcripts of 1.6, 3.3, and 6.3 kb. Although the functional consequences of these different 3'-end mRNAs are not known, they may show altered stability or cellular localization. In addition to the alternative splicing in the 3'-end of the SPEC1 mRNA, we identified by EST database searches an alternatively spliced isoform from within the SPEC1 coding region. This isoform, SPEC1- $\beta$ , was detected by RT-PCR as a minor transcript

in a variety of human tissues. Interestingly, the mechanism by which the SPEC1- $\beta$  mRNA transcript is produced involves intron retention. Intron retention occurs in other genes and frequently occurs in cancer. For instance, there is an aberrant inclusion of intron 9 in CD44 transcripts in tumor tissues, including bladder cancer, breast cancer, ovarian cancer, and gastrointestinal tumors (Matsumura et al., 1995; Yoshida et al., 1995; Bolodeoku et al., 1996). Although SPEC1- $\beta$  is present at low levels in a variety of normal tissues, it is possible that this isoform may occur more frequently in tumor tissues. Experiments using *in vitro* translation confirmed that the SPEC1- $\beta$  cDNA generates the expected 3.8 kDa protein product. Since the SPEC1- $\beta$  protein lacks a CRIB domain involved in Cdc42 binding and contains a potential membrane targeting sequence, it may function as a signaling molecule independent of Cdc42 control. Taken together, these results suggest the possibility that the SPEC1- $\beta$  protein may exist *in vivo* and may have its own unique biological activities.

Genomic analysis revealed that the AF1q gene is in a head-to-head orientation with SPEC1. AF1q is particularly interesting, because it is involved in translocations with the MLL gene and encodes a similarly small protein of 90 amino acids (Tse et al., 1995). However, unlike the ubiquitous mRNA expression of SPEC1, expression of the AF1q mRNA is restricted to hematopoietic cells (Tse et al., 1995). Although the SPEC1 gene is in close proximity to AF1q, the site of translocation with the MLL gene occurs within the first intron of AF1q (Tse et al., 1995). Analysis of the intergenic sequence between the two genes revealed promoter activity only for the SPEC1 gene. The lack of promoter activity for the AF1q gene suggests the likely possibility that additional regulatory elements are required. Along these lines, the first intron of AF1q may contain enhancer elements needed for transcriptional activity. This possibility is also supported by the fact that translocations in other genes frequently occur at sites where the chromatin is open correlating with transcriptionally active regions (Nikiforova et al., 2000; Savage, 2000). Future experiments are aimed at examining whether the first intron of AF1q contains a hematopoietic-specific enhancer.

## Acknowledgements

This work was supported by grant support from the Susan G. Komen Foundation (9851) to P.D.B., and by a DOD breast cancer pre-doctoral fellowship to D.M.P.

## References

- Bolodeoku, J., Yoshida, K., Sugino, T., Goodison, S., Tarin, D., 1996. Accumulation of immature intron-containing CD44 gene transcripts in breast cancer tissues. *Mol. Diagn.* 1, 175–181.
- Burbelo, P.D., Drechsel, D., Hall, A., 1995. A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. *J. Biol. Chem.* 270, 29071–29074.
- Burbelo, P.D., Snow, D.M., Bahou, W., Spiegel, S., 1999. MSE55, a Cdc42 effector protein, induces long cellular extensions in fibroblasts. *Proc. Natl. Acad. Sci. USA* 96, 9083–9088.
- Busson-Le Coniat, M., Salomon-Nguyen, F., Hillion, J., Bernard, O.A., Berger, R., 1999. MLL-AF1q fusion resulting from t(1;11) in acute leukemia. *Leukemia* 13, 302–306.
- Drechsel, D.N., Hyman, A.A., Hall, A., Glotzer, M., 1997. A requirement for Rho and Cdc42 during cytokinesis in *Xenopus* embryos. *Curr. Biol.* 7, 12–23.
- Dutartre, H., Davoust, J., Gorvel, J.P., Chavrier, P., 1996. Cytokinesis arrest and redistribution of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. *J. Cell Sci.* 109, 367–377.
- Hancock, J.F., Cadwallader, K., Paterson, H., Marshall, C.J., 1991. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. *EMBO J.* 10, 4033–4039.
- Hirsch, D.S., Pirone, D.M., Burbelo, P.D., 2001. A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes. *J. Biol. Chem.* 276, 875–883.
- Joberty, G., Perlungher, R.R., Macara, I.G., 1999. The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins. *Mol. Cell. Biol.* 19, 6585–6597.
- Johnson, D., 1999. Cdc42: an essential Rho-type GTPase controlling eukaryotic cell polarity. *Microbiol. Mol. Biol. Rev.* 63, 54–105.
- Kozma, R., Ahmed, S., Best, A., Lim, L., 1995. The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. *Mol. Cell. Biol.* 15, 1942–1952.
- Kroschewski, R., Hall, A., Mellman, I., 1999. Cdc42 controls secretory and endocytic transport to the basolateral plasma membrane of MDCK cells. *Nat. Cell Biol.* 1, 8–13.
- Leung, T., Chen, X., Tan, I., Manser, E., Lim, L., 1998. Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization. *Mol. Cell. Biol.* 18, 130–140.
- Makkinje, A., Quinn, D.A., Chen, A., Cadilla, C.L., Force, T., Bonventre, J.V., Kyriakis, J.M., 2000. Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. *J. Biol. Chem.* 275, 17838–17847.
- Manser, E., Leung, T., Salihuddin, H., Tan, L., Lim, L., 1993. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. *Nature* 363, 364–367.
- Manser, E., Leung, T., Salihuddin, H., Zhao, Z., Lim, L., 1994. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* 367, 40–46.
- Matsumura, Y., Sugiyama, M., Matsumura, S., Hayle, A., Robinson, P., Smith, J., Tarin, D., 1995. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. *J. Pathol.* 177, 11–20.
- Miki, H., Sasaki, T., Takai, Y., Takenawa, T., 1998. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. *Nature* 391, 93–96.
- Moore, S.L., Schaber, M.D., Mosser, S.D., Rands, E., O'Hara, M.B., Garsky, V.M., Marshall, M.S., Pompliano, D.L., Gibbs, J.B., 1991. Sequence dependence of protein isoprenylation. *J. Biol. Chem.* 266, 14603–14610.
- Nikiforova, M.N., Stringer, J.R., Blough, R., Medvedovic, M., Fagin, J.A., Nikiforov, Y.E., 2000. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. *Science* 290, 138–141.
- Nobes, C.D., Hall, A., 1995. Rho, Rac and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia and filopodia. *Cell* 81, 53–62.
- Nordeen, S.K., 1988. Luciferase reporter gene vectors for analysis of promoters and enhancers. *Biotechniques* 6, 454–458.
- Pirone, D.M., Fukuhara, S., Gutkind, J.S., Burbelo, P.D., 2000. SPECs, small binding proteins for Cdc42. *J. Biol. Chem.* 275, 22650–22656.



- Pirone, D.M., Carter, D.E., Burbelo, P.D., 2001. Evolutionary expansion of CRIB-containing Cdc42 effector proteins. *Trends Genet.* 17, 370–373.
- Qiu, R.G., Abo, A., Steven, M., 2000. A human homolog of the *C. elegans* polarity determinant Par-6 links Rac and Cdc42 to PKC-zeta signaling and cell transformation. *Curr. Biol.* 10, 697–707.
- Savage, J., 2000. Proximity matters. *Science* 290, 62–63.
- So, C.W., Ma, S.K., Wan, T.S., Chan, G.C., Ha, S.Y., Chan, L.C., 2000. Analysis of MLL-derived transcripts in infant acute monocytic leukemia with a complex translocation (1;11;4)(q21;q23;p16). *Cancer Genet. Cytogenet.* 117, 24–27.
- Symons, M., Derry, J.M., Karlak, B., Jiang, S., Lemahieu, V., McCormick, F., Francke, U., Abo, A., 1996. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase Cdc42Hs, is implicated in actin polymerization. *Cell* 84, 723–734.
- Teramoto, H., Coso, O.A., Miyata, H., Igishi, T., Miki, T., Gutkind, J.S., 1996. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. *J. Biol. Chem.* 271, 27225–27228.
- Tse, W., Zhu, W., Chen, H.S., Cohen, A., 1995. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. *Blood* 85, 650–656.
- Yoshida, K., Bolodeoku, J., Sugino, T., Goodison, S., Matsumura, Y., Warren, B., Toge, T., Tahara, E., Tarin, D., 1995. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. *Cancer Res.* 55, 4273–4277.